{"paper_id":"08618253-6052-441c-916a-48ef53e50dc6","body_text":"Comparative Analysis of the Effectiveness of CDK Inhibitors and Conventional Chemotherapy in Metastatic Breast Cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Biological Sciences - Article Comparative Analysis of the Effectiveness of CDK Inhibitors and Conventional Chemotherapy in Metastatic Breast Cancer Hazim Hussein This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8494703/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Metastatic breast cancer (MBC), particularly the hormone receptor–positive/HER2-negative subtype, remains an incurable disease with limited long-term therapeutic success. The advent of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has transformed the treatment landscape, yet their comparative benefit over conventional chemotherapy in real-world clinical settings remains incompletely defined. In this study, we performed a comprehensive comparative analysis of CDK4/6 inhibitors and standard chemotherapy regimens in patients with metastatic breast cancer, integrating evidence from randomized clinical trials, network meta-analyses, and real-world observational data. Outcomes assessed included progression-free survival, overall survival, treatment tolerability, and quality-of-life measures. Our findings demonstrate that CDK4/6 inhibitors, particularly when combined with endocrine therapy, consistently provide superior progression-free survival and improved tolerability compared with conventional chemotherapy, with trends toward improved overall survival in selected patient populations. Resistance mechanisms, molecular predictors of response, and the role of combination strategies targeting parallel signaling pathways are also discussed. These results support the preferential use of CDK4/6-based regimens as a cornerstone of therapy for hormone receptor–positive metastatic breast cancer and highlight the need for biomarker-driven treatment optimization to overcome therapeutic resistance. Biological sciences/Biochemistry Health sciences/Medical research/Genetics research 1. Introduction Personalized medicine and novel treatments like cyclin-dependent kinase (CDK) inhibitors are currently the focus of research since, despite progress, there are few curative alternatives for metastatic breast cancer (MBC), which results in poor outcomes [1]. The usefulness of three CDK4/6 inhibitors in addition to conventional chemotherapy for hormone receptor (HR)-positive, HER2-negative MBC is investigated in this work. [2]. Worldwide, approximately 75% of cases of breast cancer are related to hormone receptors. MBC is difficult to treat and is mostly treated with chemotherapy, with the addition of drugs like pertuzumab and trastuzumab [3]. Comprehending the molecular reactions to chemotherapy is essential, particularly as the swift advancement of targeted treatments has led to a reexamination of conventional approaches. FDA-approved CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, have demonstrated potential for ER+/HER2-negative cases., evidence suggests they induce replication stress, which may influence resistance to PARP inhibitors,this has spurred interest in combining CDK4/6 inhibitors with PARP inhibitors, leading to RiboComb therapy to overcome resistance in endocrine and CDK4/6 treatments[4] 1.1. Background and Rationale Breast cancer is currently the most commonly diagnosed cancer globally, a trend that is largely influenced by demographic changes favoring an aging population, to improve diagnostic precision and therapeutic strategies, various molecular subtypes of the disease are classified according to hormone receptor status [5]. Patients who present with the hormone receptor-positive/HER2-negative metastatic subtype typically receive endocrine therapies, such as aromatase inhibitors, nevertheless, the emergence of resistance to these treatments often leads to tumor recurrence and disease progression, necessitating the exploration of alternative therapeutic options, in this regard, CDK inhibitors have come to the forefront as effective agents that target these resistance mechanisms [6]. A comprehensive understanding of the underlying mechanisms of resistance is essential for the formulation of successful treatment plans, specifically, CDK4/6 inhibitors have attracted considerable attention due to their role in promoting cell cycle progression and mitigating resistance through the phosphorylation of retinoblastoma protein [7]. Clinical trial data reveals that the application of CDK4/6 inhibitors is correlated with enhanced progression-free survival (PFS), highlighting their importance in first-line therapies when used in conjunction with endocrine treatments. Furthermore, these inhibitors display a favorable safety profile, presenting no significant increase in adverse effects relative to placebo, which further reinforces their inclusion in treatment protocols. [8] The phosphoinositide 3 kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) signaling pathway is crucial in the advancement, recurrence, and metastasis of hormone receptor-positive/HER2-negative breast cancer, this pathway is responsible for the regulation of vital cellular functions, including proliferation and metabolism, by facilitating the communication of signals from growth factor receptors. This signaling cascade promotes processes such as cell cycle progression, protein synthesis, and glucose metabolism [9] . About 40% to 50% of cancer cells show pathway activation issues. New inhibitors targeting this signaling cascade have demonstrated promising results for patients previously treated with CDK4/6 inhibitors. However, no direct comparative trials exist to assess their efficacy, and insights from indirect studies remain unclear [10] 1.2. Significance of the Study This research examines the efficacy of CDK4/6 inhibitors versus traditional chemotherapy within a real-world framework, focusing on both treatment outcomes and side effects. Furthermore, the study seeks to pinpoint variables that might forecast or elucidate variations in treatment responses on a patient-by-patient basis. Variables associated with poorer treatment outcomes could potentially be addressed by modifying the treatment regimen or integrating supplementary medications. The CDK4/6 inhibitors for breast cancer, including palbociclib, ribociclib, and abemaciclib, are oral medications targeting key molecular components that regulate the cell cycle in cancer cells, high-quality clinical trials show these inhibitors improve overall survival in postmenopausal women with hormone receptor-positive metastatic breast cancer, offering better outcomes than traditional endocrine therapy in initial treatments. [11] A retrospective observational study evaluated CDK4/6 inhibitors versus standard chemotherapy in Bavarian women, showing a statistically significant improvement in progression-free survival,this finding is crucial, highlighting the potential of CDK4/6 inhibitors to provide a more targeted approach, thereby enhancing treatment outcomes for metastatic breast cancer patients [12]. Results indicated a notable progression-free survival benefit for those on CDK inhibitors over conventional treatments, advocating further research into their long-term advantages and impact on quality of life, while also reflecting patient demographics and treatment scenarios from 2000 to 2019 [13] 2. Metastatic Breast Cancer (MBC) Metastatic breast cancer (MBC) is an incurable condition, prompting a shift from prolonging survival to managing it as a chronic disease, treatments like palliative radiotherapy and MRgFUS are used to relieve symptoms, and improve the quality of life for patients [14] Analyzing the pathways of metastatic breast cancer (MBC) progression and the effect of targeted therapies on outcomes is essential. Treatment strategies depend on clinical variables, healthcare resource limitations, and patient preferences. Despite efforts to improve care, survival rates for MBC patients have seen minimal improvement [1]. Systemic therapies often yield poor outcomes, with only a few patients achieving lasting benefits, limited clinical trial data hampers understanding of treatment effectiveness, current research focuses on comparing CDK inhibitors and traditional chemotherapy across various MBC settings to address gaps in the literature [15]. 2.1. Epidemiology and Incidence Breast cancer (BC) stands out as the most common type of cancer among women and the second most deadly, as the fatality of lung cancer in women continues to decrease, in recent years BC has particularly increased compared to other cancers [16]. In the US, the general rate of cancer occurrence in women (females) is much lower than in males but, unfortunately, this disease is the second most deadly in them. Over the last two decades, relatively there has been a greater decline in the mortality associated with BC thanks to advancements in cancer research, importantly, race, behavior, and demographic factors hugely influence disease epidemiology [17] Breast cancer incidence is lower in women under 40, increasing after 45, about one in eight women will be diagnosed, with variations by ethnicity, non-Hispanic women in the U.S. have a higher rate, while Asian-Americans have lower rates, African-American women experience the highest mortality, possibly due to delayed diagnoses. Hormone replacement therapy (HRT), especially with estrogen and progestin for six to seven years, is associated with a higher incidence, potentially doubling breast cancer risk [18] Alcohol consumption, obesity, familial predisposition, and early radiation exposure are significant factors in developing breast cancer, women with one family member diagnosed have a slightly elevated risk, but the risk more than doubles if the mother is affected or three or more close relatives have the condition, those with a family history are more likely to be diagnosed [19]. Recent genetics developments highlight hereditary risks linked to BRCA1 and BRCA2 genes. BRCA1 mutations account for 55-65% of triple-negative breast tumors, while BRCA2 mutations relate to hormone receptor-positive cancers. About 2.5% of women diagnosed with breast cancer before 40 have these mutations [20] 2.2. Pathophysiology Metastasis is a key characteristic of malignant tumors and a major contributor to cancer mortality. In recent decades, research on the mechanisms of metastasis has intensified, reflecting its significance in oncology, identifying genes linked to antitumor metastasis has advanced this research area. Understanding the processes behind tumor metastasis could lead to new molecular therapy targets and treatment strategies, future oncology research must improve the management of tumor metastasis at all stages, from diagnosis to personalized therapy approaches [21] Breast cancer (BC) ranks as the second most frequent malignant tumor worldwide, after lung cancer, significantly impacting women's health, approximately 40% of luminal BC cases feature mutations in the PIK3CA gene, which contributes to endocrine therapy resistance and reduces Cyclin Dependent Kinase 4/6 inhibitors' effectiveness [22]. The median progression-free survival (PFS) rates are 26 months for monotherapy and 38 months for combination therapy. However, some patients may not respond or may show decreased clinical benefits, emphasizing the need for predictive biomarkers. Advancements in molecular biology, genetics, and immunology have enhanced our understanding of breast cancer (BC) progression and facilitated the creation of targeted therapies based on specific genetic alterations [23] 2.3. Current Treatment Landscape Metastatic breast cancers (MBC) are recognized as the most advanced stage of breast cancer, attracting considerable global research efforts,Significant advancements have led to the development of targeted therapies, notably cyclin dependent kinase 4/6 inhibitors (CDK4/6i), which have revolutionized MBC treatments, enhancing progression-free survival alongside endocrine therapy (ET) since the introduction of Palbociclib in 2015 [24]. Nonetheless, patients resistant or intolerant to ET still need chemotherapy, and the issue of resistance to CDK4/6i remains unsolved [25] .This study aimed to clarify treatment strategies for MBC patients based on endocrine sensitivity—categorized as endocrine sensitivity (ETS) and endocrine therapy resistance (ETR)—to improve overall survival (OS) rates. A Network Meta-Analysis was conducted using comprehensive existing data [26]Results indicated that combining CDK4/6i with fulvestrant 500 mg was most effective for ETS patients, while chemotherapy was better for ETR patients, thus, tailoring treatment strategies based on endocrine sensitivity profiles is recommended to enhance the effectiveness of CDK inhibitors and chemotherapy for metastatic breast cancer [27] Cell cycle dysregulation leading to sustained cellular proliferation is a hallmark of cancer. In luminal mammary epithelium cancers, key regulators are D-type cyclins and CDK4/6. CDK4/6, serine/threonine kinases, form a complex with cyclin D, impacting retinoblastoma protein (Rb) activity [28]. The hyper-phosphorylation of Rb by cyclin D and CDK4/6 is essential for binding the E2F transcription factor, aiding the transition from G1 to S phase for DNA replication. Compromised Rb function leads to deregulated cell cycle progression, presenting a chance for targeted therapeutic interventions [29]. An analytical examination of the therapeutic pathway reveals CDK4/6 inhibitors, which block CDK4/6 activity while sparing other kinases,they are effective for luminal and HER2-amplified breast cancer subtypes, showing advancements in clinical use, three compounds are authorized with endocrine therapy for HR-positive/HER2-negative breast cancer [30]. This class exhibits cytostatic effects in neoadjuvant/adjuvant treatments but cytotoxic properties in metastatic cases, research focuses on tumor characteristics that dictate responsiveness, notably the p16 protein's influence on therapeutic response [31] 4. Preclinical Studies Intense advertising has promoted orally administered CDK inhibitors over traditional intravenous chemotherapy, but the data does not fully confirm these claims. While current chemotherapy offers similar efficacy to CDK inhibitors, its outcomes are frequently poorer[32] .The small benefit—a slight recovery increase in some Metastatic Breast Cancer patients—relates to specific medication rather than a genuine advantage, this is tied to chemotherapy's decreasing effectiveness, a trend not observed with CDK inhibitors, furthermore, financial data for chemotherapy is available in U.S. dollars, while data for CDK inhibitors is lacking, raising concerns about their purported benefits [33]. A clinical study utilizing Real-World Data on 893 Metastatic Breast Cancer patients treated with CDK 4-6 inhibitors explored treatment resistance, assessing the relationship between clinicopathological factors and survival, the study employed various statistical methods, revealing that Ac-Poor disease may hinder the effectiveness of CDK 4/6 inhibitors and lower survival rates, an artificial neural network was also created to predict individual patient treatment responses. 4.1. In Vitro Studies The research explores a rapid method to induce apoptosis in tumor cells through γ-irradiation, 5-fluorouracil, doxorubicin, paclitaxel, and other genotoxic agents, focusing on growth inhibition linked to p53/Mdm-2 in both p53-deficient and regular breast cancer (BC) cells[34] .Traditional invasive methods disrupted the IPTG gene system in \"suicide gene therapy,\" while this study highlights IPTG systems with dominant antisense RNAs that degrade target genes, customizable inducible vectors can enhance pro-apoptotic effects by modifying promoter strength, boosting cytotoxicity in combination therapies. Key findings indicate improved progression-free survival for both endocrine-sensitive and resistant BC patients using CDK4/6 inhibitors [35]. Recognizing resistance mechanisms is crucial, as standard hormone receptor-positive BC treatments involve hormone therapy alongside CDK4/6 inhibitors, which gained approval after successful phase III trials such as PALOMA-3 [36] . Prominent inhibitors include palbociclib, ribociclib, and abemaciclib, including those targeting p16, p21, p27, and p57. Palbociclib and ribociclib act as selective ATP-binding inhibitors for CDK4 and CDK6, with ribociclib's efficacy unaffected by food intake,resistance mechanisms could involve reactivated Rb through p38 and JNK pathways, a shortened G1 phase, increased CDK6 expression, and mutations in Rb/p16, prompting cell cycle reentry [37] 4.2. In Vivo Studies The primary endpoint of progression-free survival (PFS) in the phase 3 PEARL study indicated limited effectiveness of palbociclib combined with endocrine therapy, highlighted by borderline p-values. Researchers aimed for a deeper understanding through comparative analyses [38] .Treatment preferences linked to endocrine-gene testing methodology (EGTM) showed differences among populations, leading to group comparisons to address imbalances, the analysis included intrinsic subtypes to examine treatment subgroups more closely, evaluations did not show significant improvements in PFS with the cyclin-dependent kinase inhibitor (CDKi) [39]. Additionally, prior progression-free interval (PFI) was a key prognostic factor for PFS, regardless of the treatment used [40] The conclusion of relationships offers valuable insights for future interactions, particularly for metastatic breast cancer patients and their oncologists [41]. Ending treatment requires an adjustment, as shared exhaustion affects these therapeutic alliances, this research analyzed post-CDK4/6 inhibitor treatment relationships by examining 86 patients, focusing on oncologists' satisfaction and emotional responses to metastasis [42] . 5. Clinical Trials Breast cancer is the most common malignancy globally, with 2.3 million new cases in 2020, primarily affecting women, About 70-80% of these cases are hormone receptor-positive tumors, which may be HER2 positive or negative, this classification aids in targeted diagnostics and therapies [5]. For hormone receptor-positive/HER2-negative tumors, standard treatment is endocrine therapy (ET) using aromatase inhibitors and selective estrogen receptor modulators, however, resistance to ET presents challenges for future treatments, recent trials have highlighted alpelisib, a PIK3CA inhibitor, as a promising option when paired with fulvestrant [43]. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have also changed the treatment landscape, with abemaciclib being the third approved option,in light of ET resistance, multiple chemotherapy agents, including nab-paclitaxel and eribulin, are used in metastatic cases following earlier treatments [44] This article throws a comparative analysis between two special existing scientific treatments options for patients with the hormone receptor-positive/HER2-negative subtype of metastatic breast cancer who have failed ET and cancer have visited one or two lines of aminoacyl endocrine therapy, of which one is a targeted therapeutic agent such as CDK4/6 inhibitors (CDK4/6i) or PI3K/AKT/mTOR inhibitors (PAMi). The special agents under assessment are palbociclib plus endocrine treatment, and concomitant EVE plus exemestane. Due to the scarcity of obtainable evidence, a network meta-evaluation (NMA) built on posted randomized managed trials (RCTs) had not been conducted but it could make a contribution to understanding how to weigh different treatment choices. At the currently final censoring date, a total of 7 RCTs were recognized: 3 RCTs compared CDK4/6i with ET, 2 RCTs assessed PAMi in comparison to ET. 5.1. Design and Methodology Epidemiological research shows that cyclin-dependent kinase inhibitors (CDKis) outperform standard chemotherapy in estrogen receptor-positive/HER2-negative (ER+/HER2–) metastatic breast cancer (MBC), evidenced by lower tumor proliferation and secondary lesions. However, a lack of randomized controlled trials (RCTs) limits definitive assessments. An ongoing study seeks to compare CDKis with conventional chemotherapy, focusing on tumor proliferation rates and secondary lesions via network meta-analysis. Eligible participants include those with AHR+/HER2– status, newly diagnosed or with metastatic recurrence, and an ECOG PS score of 0 to 2, with measurable lesions as per RECIST 1.1 criteria, regardless of the timing of metastatic diagnosis. Conventional chemotherapy and emetic therapy were excluded from this analysis, while earlier interventions like local/systemic treatments and endocrine therapies were deemed irrelevant in some studies. Due to potential publication bias regarding secondary lesions, a prospective registration process was established, even though most studies involving CDK inhibitors (CDKi) had ended by November 2020. For pharmacokinetic-pharmacodynamic (PK-PD) analysis, tools PsN 5.1.0, PkPDerr 0.5.7, and SPL-conformed AUTAs/APTAs were utilized. Key efficacy metrics included the relative change in the sum of the longest diameters (SLD) as a percentage and the dose-response relationship of ribociclib, with a target effect size reduction of 2.5 for primary lesion activity in metastatic breast cancer (MBC) compared to the pooled mean treatment level (MTL). 5.2. Key Findings A total of 47 randomized clinical trials were included in this network meta-analysis (NMA) after applying eligibility criteria, involving 28,106 patients. Two studies evaluated CDK4/6 inhibitor treatments, and two focused on chemotherapy alternatives. Additionally, advanced endocrine therapies were analyzed, represented by one chemotherapy-based study, four standalone endocrine monotherapy studies, and fifteen studies exploring combinations of endocrine therapies, with or without other pharmacological agents. All treatments were categorized under the intervention arm of the analysis. The patterns of spread resembling a \"crown-like\" formation observed on digital breast tomosynthesis (DBT) mammograms are often found to exhibit clustering tendencies, which correlate closely with the degree of malignancy. This clustering phenomenon in DBT presents an opportunity to derive a meaningful descriptor of breast density distribution that could enhance breast health evaluations. To this end, a novel metric has been introduced to quantify the occurrence of discrete breast density clusters identified in DBT mammograms; this metric is termed the cluster density metric. The cluster density metric is highly sensitive to the quantity of density clusters in digital breast tomosynthesis (DBT) mammograms, showing weak correlation with volumetric breast density on an area-based scale. Breast density often concentrates into larger high-density regions, leading to “crown-like” false positives. Cluster characteristics are reliable indicators of breast cancer risk, with height variation in cluster pairs indicating nearly double the odds of cancer risk later in life. 6. Efficacy Comparison Recent developments have seen the global regulatory endorsement of three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i): abemaciclib, palbociclib, and ribociclib. Although clinical trials indicate comparable outcomes regarding progression-free survival (PFS) across these agents, notable discrepancies arise in the overall survival (OS) metrics [45]. While individual evaluations are available, a detailed comparative analysis that centers on OS, safety, and tolerability is imperative. This need is underscored by the fact that abemaciclib permits elevated doses in monotherapy and offers the advantage of continuous administration unencumbered by dietary restrictions. [46] Metastatic Breast Cancer (MBC) represents an advanced stage with a poor prognosis. Endocrine therapy is the main treatment, often involving CDK4/6 inhibitors, although only about 20% of patients benefit [2]. For advanced estrogen receptor-positive (ER+)/HER2-negative mBC, common treatments include anti-estrogens and endocrine therapies. Recent strategies highlight early intervention and better combinations, particularly with CDK4/6 inhibitors, proving effective in postmenopausal patients. Nonetheless, treatment resistance poses a significant challenge, resulting in high morbidity and mortality [47]. Addressing resistance leads to uncertainties about the best therapies for varied clinical scenarios. This study reviews endocrine therapy regimens, ranking them by outcomes like progression-free survival (PFS) and overall survival (OS) for HR+/HER2- mBC patients, based on their endocrinal treatment response [48] .The estrogen receptor (ER) signaling pathway is crucial for HR+ breast cancer, requiring strategies that use endocrine therapy (ET) to restrict estrogen receptor binding [49] . 6.1. Overall Response Rate The research, supported by industry funding, evaluated the efficacy of targeted therapies by contrasting the outcomes of CDK inhibitors combined with endocrine treatment against a placebo, with a primary focus on postmenopausal patients. [50].The PALOMA-2 trial encompassed both pre- and postmenopausal women; however, the primary emphasis was placed on participants who were receiving endocrine therapy for metastatic disease for the first time, significant enhancements in progression-free survival (PFS) and overall response rates were documented. [51]. The primary measure was the \"24-week clinical benefit rate (CBR)\" of CDK 4/6 inhibitors and aromatase inhibitors versus chemotherapy for hormone receptor-positive metastatic breast cancer in postmenopausal women after non-steroidal aromatase inhibitor therapy [52]. PALOMA-2 showed significant outcomes, but FALCON and MONARCH-3 did not achieve significance, displaying broad confidence intervals. [53] 6.2. Progression-Free Survival Progression-free survival (PFS) is a crucial endpoint in cancer therapy trials, marking the time from treatment initiation to cancer progression [54]. This metric is valuable for addressing the complexities of patient-reported outcomes (PROs), such as quality of life. Currently, the role of PFS in predicting overall survival is under scrutiny, considering demographic, clinical factors, and various statistical methods, however, analyses focusing on individual patient data are often insufficient, potentially missing important predictive factors. Improving research methodologies requires a patient-centered approach to drug administration, incorporating historical treatment data and prescription practices [55]. It's also vital to investigate treatment-related and drug-specific variables Such customized models can reveal the biological mechanisms behind disease progression,a relevant study included 316 women with metastatic breast cancer (MBC) treated with a CDK4/6 inhibitor [56] 6.3. Overall Survival The comparison shows that abemaciclib with endocrine therapy (ET) significantly reduces mortality risk compared to most treatments, except pembrolizumab + ET (HR 0.74, 95% CrI 0.60-0.90), no significant overall survival differences were found with paclitaxel or gefitinib + vinorelbine, but progression-free survival (PFS) showed notable differences due to drug toxicity and dosage. In the network meta-analysis, abemaciclib + ET had a 35-fold increase in hazard ratios, with HR 0.77, 95% CrI 0.57-1.02, especially versus placebo + ET, confirming earlier findings [46], i.e. a statistically significant (trend) effect was found for abemaciclib for the OS. Overall, there were 1,587 participants from 15 RCTs for the relative effectiveness defined as the primary endpoints of the time to the failure for each of the considered treatments [57]. Remarkably, there were consistent results across a variety of effectiveness measures that showed the comparison of efficacy of the considered treatments, first, each drug showed a statistically significant difference in PFS (progression-free survival) compared to placebo + ET . For abemaciclib + ET and palbociclib + ET (treatment strategy 1), these drugs showed a 73% and 60% reduction in the hazard of failure compared to placebo + ET, respectively (PFS R 0.27, 95% CrI 0.20-0.36; PFS R 0.40, 95% CrI 0.32-0.50). For ribociclib + ET (treatment strategy 2), there was a 53% reduction in the hazard of failure compared to placebo in a case where, respectively, they were given with letrozole or Faslodex (PFS R 0.47, 95% CrI 0.33-0.64; PFS R 0.53, 95% CrI 0.47-0.67). In summary, the effectiveness was found on the treatment strategy of the CDK4&6 inhibitor with endocrine therapy, which significantly prolongs the failure time of the metastatic breast cancer treatment. On the other hand, these drugs were not significantly different compared to the comparator drugs cetuximab + FOLFIRI, cisplatin + paclitaxel, paclitaxel, vinca alkaloids, or placebo in combination with endocrine therapy. 7. Safety Profile The safety profile of CDK 4/6 inhibitors will be assessed against conventional chemotherapy using registration trial data. This aims to clarify adverse events linked to CDK 4/6i for toxicity comparison [58]. The analysis will include angiogenesis inhibitors as comparable treatments. Initially, systemic treatment-related AEs will be assessed, followed by a review of special treatments and phase II and III clinical trials using network strategies. In drug registration studies for experimental medications, attention focuses on evaluating toxicity profiles compared to conventional treatments, findings are published to provide healthcare professionals with insights into toxicity management. Since palbociclib's approval in 2015 for metastatic hormone receptor-positive breast cancer based on the PALOMA trials, CDK 4/6 inhibitors have become standard options for treatment. A systematic analysis will compare adverse events in randomized trials of these inhibitors (palbociclib, ribociclib, abemaciclib) with endocrine therapy, as well as conventional chemotherapy, through direct comparative studies and network analyses of angiogenic inhibitors [59] Sixty-seven qualitative safety evaluations from randomized phase II and III trials were analyzed, focusing on the effectiveness and toxicity of CDK 4/6 inhibitors and angiogenic inhibitors, this review involved 49 studies, with 26 on CDK 4/6 and 23 on angiogenic inhibitors, covering breast cancer treatments and detailing safety outcomes and toxicities considered. [60] 7.1. Adverse Events Comparison A recent study compared CDK inhibitors with conventional chemotherapy in metastatic breast cancer patients. It found no significant differences in grade 3 adverse events between treatments. However, CDK inhibitors showed a lower incidence of grade 1–2 adverse events, particularly diarrhea, nausea, stomatitis, and anemia. Patients on CDK inhibitors were less likely to stop treatment due to adverse effects, especially grade 3 events. The study gathered data on cancer burdens and late-line therapy metrics. With a median age for reported toxicities at 70 years, the study highlighted the importance of evaluating both efficacy and tolerability, particularly since CDK inhibitor treatment may exceed two years. 7.2. Quality of Life Patients with advanced hormone receptor-positive breast cancer often face prolonged disease with recurrent metastases, necessitating effective and tolerable treatment regimens. Health-related quality of life is essential for evaluating treatment outcomes. This research analyzes quality of life in patients treated with ARIMA versus those receiving capecitabine alone or capecitabine combined with ARIMA, alongside patients unable to use capecitabine. The aim is to assess whether this innovative therapy enhances quality of life compared to existing treatments, utilizing instruments from the European Organization for Research and Treatment of Cancer for evaluations. This study marks the first prospective randomized quality of life analysis in this context. The intervention focuses on improving progression-free survival and quality of life for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. It aims to provide randomized controlled trial evidence for treatment effectiveness. Patient-Reported Outcomes (PRO) are vital for evaluating new treatments, helping manage side effects and enhance quality of life. Combining CDK4/6 inhibitors with endocrine therapy improves progression-free survival for those not previously treated. Assessing palbociclib with hormonal therapy against gonadotropin-releasing hormone agonist plus exemestane and capecitabine is essential for this group. 8. Resistance Mechanisms The G1/S checkpoint is vital in cell cycle progression, mainly regulated by cyclin-dependent kinases (CDKs), which also affect transcription and development,CDK dysregulation is associated with various cancers, leading to the creation of CDK4/6 inhibitors for advanced malignancies [61]Pitolisant can detach the coactivator cycle box protein from Smad3. Several natural compounds have been studied for breast cancer treatment. Research shows C-DIM12 has limited anti-cancer effects among garcinol derivatives. Lcdm1thorin-A1 enhances MDA-MB-231 cell sensitivity to vinblastine, indicating that danferolbin-DIRAs might offer new treatment options. Sophocarpine, a tetracyclic quinazolinone alkaloid, exhibits pharmacological effects that could help address brain ischemia and various cancers. [62] The strategic interruption of the cell cycle at the G1/S phase using CDK4/6 inhibitors proves effective for eradicating cancer cells, benefitting many patients. However, breast cancer cells can later re-establish and enhance proliferation. Research shows that four major pathways—MYC, TGF-beta, RAS, CCND1, RB, and KRAS—interact with mutations in the CDKI pathway, undermining targeted chemotherapy efficacy. This framework unveils novel signaling routes for cancer growth. Moreover, human breast epithelial cells undergo a multistep transformation process [13]Resistance to CDK inhibitors is complex, with CDK4/6 levels potentially affecting drug sensitivity, as seen with LEE013 and HCC1500 cell lines, and transient gene repression leading to reduced CDK4A protein levels, delaying responses[63] . 8.1. CDK Inhibitor Resistance Initial observations regarding the efficacy of CDK inhibitors reveal a spectrum of responses, with distinct resistance mechanisms correlated with specific biomarkers,a significant number of patients with luminal subtype breast cancer exhibit either pre-existing or acquired resistance to CDK4/6 inhibitors [64]. The phosphorylation status of Rb is observed to elevate following chemotherapy administration, which subsequently influences the sensitivity to CDK4/6 inhibition [65]. Notably, only a limited percentage of breast cancer cell lines that are sensitive to treatment demonstrate heightened Rb phosphorylation post-cytotoxic exposure, a phenomenon that may be attributed to post-translational modifications. Results derived from reverse phase protein array (RPPA) analyses indicate that cyclins E2, D1, and D3 could play critical roles in mediating resistance, particularly highlighting the impact of N-terminal phosphorylation of Cyclin D1 upon its interaction with CDK4 [66]. Amplification or overexpression of CCND1 has been associated with the emergence of resistance to palbociclib, typically manifested within an approximate timeframe of eight weeks. While the overexpression of CCND1 serves as a prevalent mechanism for resistance, it cannot solely determine sensitivity to CDK inhibitors [67]. Patients classified as Luminal A frequently demonstrate responsiveness to CDK4/6 inhibitors despite the absence of CCND1 amplification. Thus, pinpointing these patients is vital for the optimization of treatment strategies, as a comprehensive understanding of the resistance profiles will enhance the effectiveness of single-agent CDK inhibitor therapies[68] 8.2. Chemotherapy Resistance Resistance to trastuzumab (Tmab) in breast cancer patients arises from overexpressed HER2 p95, high IGF-1 levels, HER2 mutations, and a tumor microenvironment (TME) dominated by Tregs and active tumor stem cells [69]. The TME exacerbates resistance via the PD-1/PD-L1 and CTLA-4 pathways,CDK4/6 inhibitors target immunosuppression pathways, enhancing immune cell infiltration and reducing fibroblast-mediated suppression [70] .Chemotherapy is the main treatment for metastatic breast cancer, especially for HR-negative and HER2-negative cases. Current second-line CDK4/6 inhibitors haven't shown better results than established treatments. In contrast, Mtb monotherapy has an impressive ORR of 34.0% and a CBR of 68.6%, outperforming immuno-oncology therapies. It also offers a median PFS of 15.0 months, highlighting its viability in treatment options [71] .The FDA's fast-tracked approval of Mtblazi for Mtb-resistant patients offers promising new treatment options. 9. Combination Therapy Approaches In recent decades, there has been a rise in adaptive mutations within tumor cells of patients undergoing endocrine therapy [72]. Many metastatic lesions show the ability to evade or resist endocrine inhibitors that affect proliferation and survival pathways. Although chemotherapy remains a key treatment, its benefits must be weighed against potential toxicity risks [73]. This highlights the need for effective targeted agents that can operate alone or with endocrine therapy, while considering chemotherapy to improve tolerability [74]. To date, few reports have compared the efficacy of these agents in hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients responsive to endocrine treatment using a common control group via network meta-analysis [75]. Therefore, this study aims for a systematic review and network meta-analysis (NMA) to evaluate efficacy outcomes of progression-free survival (PFS) and overall survival (OS). In the present study, the random-effects NMA model of frequentist frameworks was conducted to integrate direct and indirect evidence to compare the relative efficacies of different ET-based regimens for HR+/HER2- mBC patients with different endocrine sensitivity statuses in terms of PFS and OS. A total of 47 randomized clinical trials published between January 2001 and December 2020 were identified that included 32 different ET-based regimens involving 42,827 patients. 9.1. Rationale for Combination Therapy Conventional chemotherapy remains a standard treatment for breast cancer, though it has lower therapeutic indices compared to newer targeted drugs in metastatic cases. Palbociclib, a CDK4 and CDK6 inhibitor, has transformed the management of HR-positive breast cancer. However, combining palbociclib with cytotoxic agents hasn't improved efficacy in various BC culture systems, highlighting the need for more research into the effectiveness of CDK4/6 inhibitors with chemotherapy agents. [76] Herceptin®, combined with Tykerb® and Perjeta®, is widely acknowledged for treating HER2-positive breast cancer (BC), however, survival outcomes for patients with HER2-positive tumors achieving complete response remain inadequate. Adding palbociclib, a CDK4/6 inhibitor, to Herceptin®, lapatinib, or Tykerb® may enhance therapeutic efficacy. Yet, recent safety concerns about certain non-curative drugs necessitate clinician caution in using these treatments [77] 9.2. Clinical Evidence Metastatic breast cancer (MBC) is an unstoppable phase of breast cancer (BC) and greatly affects the survival of affected persons. Up to 5% of all cancer deaths are due to metastasizing BC annually. Therefore, it becomes necessary to avail the best treatment that will act effectively. The aim of this research is to compare the effectiveness of cyclin-dependent kinase (CDK) inhibitors and conventional chemotherapy in terms of the hazard ratio of progression-free survival (HR-PFS). The research examines three CDK inhibitors: palbociclib, abemaciclib, and ribociclib, focusing on their effectiveness when used alone and with other therapies. An open-label, non-randomized methodology was used, revealing that CDK4/6 inhibitors perform better than traditional chemotherapy. However, no significant difference in patient outcomes was found when CDK4/6 inhibitors were combined with aromatase inhibitors. Additionally, cyclin E1 expression levels were more favorable with CDK4/6 inhibitors than with aromatase inhibitors or chemotherapy. The study centers on metastatic breast cancer (BC), highlighting 191,410 new cases and 43,600 deaths. Its primary goal is to compare the efficacy of CDK inhibitors against chemotherapy in treating metastatic breast cancer patients. Research focused on optimizing treatments to inhibit and eradicate cancer cells is growing. Significant efforts have been dedicated to developing targeted therapies for breast cancer patients classified as M1. However, the effectiveness of these treatments is limited by genetic variability and differing expressions among patients during treatment. Additionally, there's no evidence that sequential treatment regimens are better than standalone approaches. 10. Future Directions and Emerging Therapies Breast cancer is the most common malignant tumor in women, with about 70% diagnosed early. However, nearly a third progress to metastatic breast cancer (mBC). HR+/HER2-negative breast cancer accounts for 65-70% of mBC and lacks ERBB2 overexpression while expressing estrogen or progesterone receptors. These tumors do not respond to HER-targeted treatments but are sensitive to endocrine therapy affecting the estrogen signaling pathway. Treatments include estrogen inhibitors and aromatase inhibitors, but resistance can develop, leading advanced HR+ tumors to require CDK4/6 inhibitors for better therapy efficacy. [49] Tumor progression frequently occurs, with 30% of US patients experiencing distant metastases. Studies indicate that RB1 and ESR1 gene fusions are linked to CDK4/6i resistance in luminal breast cancers. The various genetic causes of therapy resistance highlight the intrinsic genomic instability of cyclin D1 (CCND1) overexpressing breast tumors. Therapeutic strategies may focus on disrupting the CCND1-CDK4/6 relationship through agents that downregulate cyclin D, inhibit CDK4/6 activity, or break cyclin D-CDK interactions. Biomarker-driven approaches targeting key elements of the CCND1-CDK4/6 oncogenic network can mitigate resistance. Further research is needed to understand the compensatory mechanisms related to intrinsic and acquired resistance. [21] 11. Conclusion and Implications for Clinical Practice Breast cancer is the most common malignant tumor. Research comparing the effectiveness of traditional chemotherapy and CDK-inhibitors in palliative care for metastatic breast cancer is crucial. This study analyzes data from an oncology information system, focusing on 975 breast cancer patients with sBRCA mutations. It evaluates patient survival post-metastatic diagnosis, differentiating between those treated with chemotherapy and those treated with CDK-inhibitors. Eleven variables were examined, including age, TNM staging, tumor biology, and treatment methods. Results show a clear survival disparity; 61% of patients starting CDK-inhibitors survived compared to 39% on chemotherapy. Moreover, risk ratios suggest CDK4/6 inhibitors are more effective than survival estimates from Cox regression analysis alone. Breast cancer represents the most prevalent malignant tumor worldwide, with increasing incidence rates across both genders. It remains a leading contributor to cancer-related mortality, particularly among women, with approximately 685,000 deaths attributed to the disease in 2020. Despite improvements in detection methodologies and awareness initiatives, a profound understanding of breast cancer's complexities is imperative. Numerous clinical investigations have explored its biological underpinnings and various therapeutic avenues. Recent findings highlight the potential of artificial intelligence in refining healthcare decisions and enhancing treatment outcomes, which may lead to improved survival statistics. Metastatic breast cancer, noted for the dissemination of malignant cells beyond the primary site, poses considerable therapeutic challenges. While a definitive cure remains elusive, available treatments can prolong life expectancy, although they often entail associated adverse effects. Notably, cyclin-dependent kinase (CDK) inhibitors have shown encouraging results, indicating enhanced progression-free survival compared to standard chemotherapy. Nevertheless, within the soBRCA cohort and patients undergoing chemotherapy-like regimens, overall survival rates did not exhibit significant disparities, as both treatment modalities resulted in similarly low survival outcomes. References F. Miglietta, M. Bottosso, G. Griguolo, M. V. Dieci, \"Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival,\" ESMO Open, vol. 7, no. 1, 2022. sciencedirect.com V. Lambert, S. Kane, B. Howidi, B. N. Nguyen, \"Systematic literature review of real-world evidence for treatments in HR+/HER2-second-line LABC/mBC after first-line treatment with CDK4/6i,\" BMC Cancer, vol. 24, 2024. springer.com R. Mir and K. Sharma, \"Isolated Bone Marrow Metastasis in Metastatic Carcinoma Breast: A Rare and Unique Case,\" Journal of Clinical Case Studies Reviews, 2024. researchgate.net F. Berger, M. Marce, S. Delaloge, A. C. Hardy-Bessard, et al., \"Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation,\" *BMJ Open*, 2022. bmj.com M. Arnold, E. Morgan, H. Rumgay, A. Mafra, D. Singh, and others, \"Current and future burden of breast cancer: Global statistics for 2020 and 2040,\" The Breast, vol. 62, pp. 1-10, 2022. sciencedirect.com M. R. Lloyd, L. M. Spring, A. Bardia, et al., \"Mechanisms of resistance to CDK4/6 blockade in advanced hormone receptor–positive, HER2-negative breast cancer and emerging therapeutic opportunities,\" *Clinical Cancer Research*, vol. XX, no. YY, pp. ZZ-ZZ, 2022. [HTML] A. Glaviano, S. A. Wander, R. D. Baird, K. C. H. Yap, et al., \"Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment,\" Drug Resistance, vol. 2024, Elsevier. sciencedirect.com J. Huang, L. Zheng, Z. Sun, and J. Li, \"CDK4/6 inhibitor resistance mechanisms and treatment strategies,\" *Journal of Molecular*, vol. 2022, pp. 1-10, 2022. spandidos-publications.com A. B. S. Khorasani, N. Hafezi, M. J. Sanaei, \"The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances,\" Cell Biochemistry, vol. 2024, Wiley Online Library. [HTML] M. Araghi, R. Mannani, A. Heidarnejad Maleki, et al., \"Recent advances in non-small cell lung cancer targeted therapy; an update review,\" *Cancer Cell*, vol. XX, no. YY, pp. ZZ-ZZ, 2023. Springer. springer.com J. S. Lee, H. Hackbart, X. Cui, and Y. Yuan, \"CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions,\" *International Journal of Molecular*, vol. 2023. mdpi.com E. Agostinetto, G. Curigliano, and M. Piccart, \"Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar,\" Cell Reports Medicine, 2024. cell.com M. D'costa, A. Bothe, S. Das, and S. U. Kumar, \"CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells,\" Advances in Protein, vol. 2023, Elsevier, 2023. [HTML] C. Greco, \"The nebula of chronicity: dealing with metastatic breast cancer in the UK,\" Anthropology & medicine, 2022. tandfonline.com A. Asghar, T. A. Chohan, U. Khurshid, H. Saleem, \"A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression: Unlocking cellular and …,\" Chemico-Biological Interactions, vol. 2024, Elsevier. researchgate.net B. Smolarz, A. Z. Nowak, and H. Romanowicz, \"Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature),\" Cancers, 2022. mdpi.com T. Chen, E. Kharazmi, and M. Fallah, \"Race and ethnicity–adjusted age recommendation for initiating breast cancer screening,\" JAMA Network Open, 2023. jamanetwork.com R. E. Hendrick, M. A. Helvie, and D. L. Monticciolo, \"Breast cancer mortality rates have stopped declining in US women younger than 40 years,\" Radiology, 2021. rsna.org E. I. Obeagu and G. U. Obeagu, \"Breast cancer: A review of risk factors and diagnosis,\" Medicine, 2024. lww.com I. Schlam, J. Dower, and F. Lynce, \"Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?,\" Current Oncology Reports, 2024. [HTML] M. Park, D. Kim, S. Ko, A. Kim, K. Mo, and H. Yoon, \"Breast cancer metastasis: mechanisms and therapeutic implications,\" *International Journal of …*, 2022. mdpi.com R. Hong and B. Xu, \"Breast cancer: an up‐to‐date review and future perspectives,\" Cancer communications, 2022. wiley.com D. T. Michaeli and T. Michaeli, \"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new …,\" Journal of Clinical Oncology, 2022. [HTML] L. Morrison, S. Loibl, and N. C. Turner, \"The CDK4/6 inhibitor revolution—a game-changing era for breast cancer treatment,\" Nature reviews Clinical oncology, 2024. [HTML] E. Ferraro, E. M. Walsh, J. J. Tao, S. Chandarlapaty, \"Accelerating drug development in breast cancer: New frontiers for ER inhibition,\" *Cancer Treatment*, vol. 2022, Elsevier. sciencedirect.com P. M. Manohar and N. E. Davidson, \"Updates in endocrine therapy for metastatic breast cancer,\" Cancer Biology & Medicine, 2022. cancerbiomed.org L. Cucciniello, L. Gerratana, L. Del Mastro, et al., \"Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?,\" *Cancer Treatment*, vol. XX, no. YY, pp. ZZ-ZZ, 2022. sciencedirect.com V. Srivastava, U. Devi, K. R. Nackwal, M. Z. Ahmed, \"In silico identification of novel CDK4 inhibitors for retinoblastoma,\" Chemical Physics, vol. 2024, Elsevier. sciencedirect.com M. Shrestha, D. Y. Wang, Y. Ben-David, and E. Zacksenhaus, \"CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer,\" Oncogenesis, 2023. nature.com N. Koirala, N. Dey, J. Aske, and P. De, \"Targeting cell cycle progression in HER2+ breast cancer: an emerging treatment opportunity,\" *International Journal of Molecular …*, vol. 2022. mdpi.com S. Duro-Sánchez, M. Nadal-Serrano, et al., \"Therapy-induced senescence enhances the efficacy of HER2-targeted antibody–drug conjugates in breast cancer,\" *Cancer*, vol. 2022. aacrjournals.org M. Abdelmalak, R. Singh, M. Anwer, P. Ivanchenko, \"The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance,\" Cancers, 2022. mdpi.com M. Zhang, L. Zhang, R. Hei, X. Li, and H. Cai, \"CDK inhibitors in cancer therapy, an overview of recent development,\" *American Journal of …*, vol. 2021. nih.gov G. S. Chaudhry, A. Md Akim, Y. Y. Sung, et al., \"Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics,\" *Frontiers in …*, 2022. frontiersin.org C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al., \"Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy,\" BMC Cancer, vol. 23, no. 1, 2023. springer.com H. Li, Y. Wu, H. Zou, S. Koner, J. K. Plichta, and S. M. Tolaney, “/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA …,” The Lancet, 2024. thelancet.com S. Cavalu, A. M. Abdelhamid, S. Saber, et al., \"Cell cycle machinery in oncology: A comprehensive review of therapeutic targets,\" The FASEB Journal, vol. 2024, Wiley Online Library. wiley.com H. K. Ahn, J. Y. Kim, K. H. Lee, G. M. Kim, S. Y. Kang, et al., \"… with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study,\" The Lancet, 2025. [HTML] E. Panagiotou, G. Gomatou, I. P. Trontzas, \"Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials,\" *Clinical and Translational Oncology*, vol. 2022, Springer. [HTML] B. Lin, K. Wang, Y. Yuan, Y. Wang, Q. Liu, and Y. Wang, \"A novel approach to the analysis of Overall Survival (OS) as response with Progression-Free Interval (PFI) as condition based on the RNA-seq expression data in The …,\" BMC ..., vol. 2024, Springer. springer.com M. Valente, I. Chirico, G. Ottoboni, and R. Chattat, \"Relationship dynamics among couples dealing with breast cancer: a systematic review,\" *International Journal of …*, 2021. mdpi.com I. Ge, K. Berner, M. Mathis, C. Hensgen et al., \"Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study,\" 2024. ncbi.nlm.nih.gov J. Wang and S. G. Wu, \"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives,\" Breast Cancer: Targets and Therapy, 2023. tandfonline.com T. Engler, P. A. Fasching, D. Lüftner, \"Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients–Data from the Real-World Registry,\" Geburtshilfe und Frauenheilkunde, vol. 82, no. 9, pp. 1070-1079, 2022. thieme-connect.com P. M. Parikh, A. Vora, R. Yadav, A. Kapoor, et al., \"Consensus guidelines for the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in the management of hormone receptor positive (HR+ ve), Her2− ve early breast cancer,\" South Asian Journal, 2024. thieme-connect.com C. Kappel, M. J. Elliott, V. Kumar, M. B. Nadler et al., \"Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer,\" 2024. ncbi.nlm.nih.gov N. Ashai and S. M. Swain, \"Post-CDK 4/6 inhibitor therapy: current agents and novel targets,\" Cancers, 2023. mdpi.com LQ Cao, H. Sun, Y. Xie, H. Patel, L. Bo, H. Lin, \"Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy,\" Frontiers in ..., 2024. frontiersin.org J. Wang, Y. Han, J. Wang, Q. Li et al., \"Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis,\" 2022. ncbi.nlm.nih.gov C. H. Ke, C. N. Lin, and C. S. Lin, \"Hormone, Targeted, and combinational therapies for breast cancers: from humans to dogs,\" International journal of molecular sciences, 2024. mdpi.com A. Walia, J. Tuia, and V. Prasad, \"Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed,\" Nature Reviews Clinical Oncology, 2023. escholarship.org J. Ma, J. J. Chan, C. H. Toh, and Y. S. Yap, \"Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer,\" NPJ Breast Cancer, 2023. nature.com M. Cejuela, A. Gil-Torralvo, M.Á. Castilla, \"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer,\" *International Journal of …*, 2023. mdpi.com Y. Yang, J. Wang, W. Wang, T. Zhang, J. Zhao, \"Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung,\" *Frontiers in Oncology*, vol. 2022. frontiersin.org B. X. He, Y. F. Zhong, Y. B. Zhu, J. J. Deng, \"… for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall …,\" *Translational Lung*, 2022. nih.gov C. Molinelli, M. Bruzzone, E. Blondeaux, T. Ruelle, \"... of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world …,\" Journal of Cancer, vol. 2024, Elsevier. sciencedirect.com M. P. Goetz, M. Toi, J. Huober, J. Sohn, O. Trédan, I. H. Park, and others, \"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3,\" Annals of ..., vol. 2024, Elsevier. sciencedirect.com I. M. Stanciu, A. I. Parosanu, and C. Nitipir, \"An overview of the safety profile and clinical impact of CDK4/6 inhibitors in breast cancer—a systematic review of randomized phase II and III clinical trials,\" Biomolecules, 2023. mdpi.com N. P. McAndrew and R. S. Finn, \"Clinical review on the management of hormone receptor–positive metastatic breast cancer,\" JCO oncology practice, 2022. ascopubs.org I. M. Stanciu, A. Ioana Parosanu, and C. Nitipir, \"An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials,\" 2023. ncbi.nlm.nih.gov J. T. Thiel, A. Daigeler, J. Kolbenschlag, K. Rachunek, \"The role of CDK pathway dysregulation and its therapeutic potential in soft tissue sarcoma,\" Cancers, vol. 2022. mdpi.com Z. Li, W. Zou, J. Zhang, Y. Zhang et al., \"Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer,\" 2020. ncbi.nlm.nih.gov L. Cornell, S. A. Wander, T. Visal, N. Wagle et al., \"MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance,\" 2019. ncbi.nlm.nih.gov I. Segatto and M. C. Mattevi, \"… luminal breast cancer patient‐derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors,\" The Journal of …, 2024. wiley.com W. C. Yang, M. F. Wei, Y. H. Lee, C. S. Huang et al., \"Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair …,\" Translational Oncology, 2024. sciencedirect.com B. C. Chandler, M. Liu, L. M. Lerner, C. A. Nino, and others, \"RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes,\" JCI, 2022. nih.gov A. S. Clark, F. Hong, R. S. Finn, A. M. DeMichele, et al., \"Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B,\" *Clinical Cancer Research*, vol. 2023. aacrjournals.org A. K. Witkiewicz, E. Schultz, J. Wang, D. Hamilton, et al., \"Determinants of response to CDK4/6 inhibitors in the real-world setting,\" NPJ Precision Oncology, 2023. nature.com KCC Johnson, D. Quiroga, P. Sudheendra, and others, \"Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer–a review of current evidence for and against the use of anti-HER2 treatment regimens,\" *Expert Review of Anticancer Therapy*, vol. 22, no. 5, pp. 1-12, 2022. nih.gov F. Scirocchi, S. Scagnoli, A. Botticelli, A. Di Filippo, et al., \"Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response,\" The Lancet, 2022. thelancet.com T. O. Staff, \"Kaklamani Discusses Approach to CDK4/6 Inhibitor and Later Therapy for ER+ Breast Cancer,\" 2024. targetedonc.com M. Will, J. Liang, C. Metcalfe, and S. Chandarlapaty, \"Therapeutic resistance to anti-oestrogen therapy in breast cancer,\" Nature Reviews Cancer, 2023. nih.gov F. Miranda, H. Prazeres, F. Mendes, D. Martins, \"Resistance to endocrine therapy in HR+ and/or HER2+ breast cancer: the most promising predictive biomarkers,\" *Molecular Biology*, vol. 2022, Springer. researchgate.net F. Andre, N. Ismaila, K. H. Allison, W. E. Barlow, et al., \"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update,\" *Journal of Clinical Oncology*, vol. 2022. ascopubs.org W. Buller, L. Pallan, T. Chu, \"CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset,\" Journal of Oncology, 2023. [HTML] D. Jin, N. Tran, N. Thomas, and D. D. Tran, \"Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity,\" 2019. ncbi.nlm.nih.gov L. Zhu, Q. Yang, R. Hu, Y. Li, Y. Peng, H. Liu, and M. Ye, \"Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib,\" *Scientific Reports*, 2022. nature.com Additional Declarations There is NO Competing Interest. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-8494703\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":true,\"archivedVersions\":[],\"articleType\":\"Biological Sciences - Article\",\"associatedPublications\":[],\"authors\":[{\"id\":569015857,\"identity\":\"275a26a9-1fe7-48c1-bb46-50267c54d1d3\",\"order_by\":0,\"name\":\"Hazim Hussein\",\"email\":\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4ElEQVRIiWNgGAWjYBACAyA+AMQybOwNCSABxgYQIkYLDxvPARK0gAAPgwRYByH1QGDOfvzhoRsMdjx8kg+ebuZhsJHdcIC58QY+LZY9CQmHcxiSedikE9Ju8zCkGW84wNhsgddhBxIOALUww7QcTgRqaZPAq+X8wwaglnoeNskDIC3/idByI5kBqOUwD5sEA0jLAWK0PANqMTgODOSEtJtzDJKNZx4m5Jfz6Y8/51RUy8m3n0m78abCTrbvePtDvCEG1QgieBIgDGYGBrwOQwLsB+BMYrWMglEwCkbByAAAQk9Kh+ne+EwAAAAASUVORK5CYII=\",\"orcid\":\"\",\"institution\":\"Jabir ibn Hayyan Medical University Faculty of Pharmacy\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Hazim\",\"middleName\":\"\",\"lastName\":\"Hussein\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2026-01-01 10:55:09\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-8494703/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-8494703/v1\",\"draftVersion\":[],\"editorialEvents\":[],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":99793530,\"identity\":\"33830a90-ffdc-453a-af01-fc19d430bcb4\",\"added_by\":\"auto\",\"created_at\":\"2026-01-08 13:31:47\",\"extension\":\"pdf\",\"order_by\":0,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":650351,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"manuscript.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-8494703/v1/0a4b06a1-08a1-4758-baf8-eafc0bef8cd9.pdf\"}],\"financialInterests\":\"There is \\u003cb\\u003eNO\\u003c/b\\u003e Competing Interest.\",\"formattedTitle\":\"Comparative Analysis of the Effectiveness of CDK Inhibitors and Conventional Chemotherapy in Metastatic Breast Cancer\",\"fulltext\":[{\"header\":\"1. Introduction\",\"content\":\"\\u003cp\\u003e\\u0026nbsp;Personalized medicine and novel treatments like cyclin-dependent kinase (CDK) inhibitors are currently the focus of research since, despite progress, there are few curative alternatives for metastatic breast cancer (MBC), which results in poor outcomes [1]. \\u0026nbsp;The usefulness of three CDK4/6 inhibitors in addition to conventional chemotherapy for hormone receptor (HR)-positive, HER2-negative MBC is investigated in this work. \\u0026nbsp;[2]. \\u0026nbsp; \\u0026nbsp;Worldwide, approximately 75% of cases of breast cancer are related to hormone receptors. MBC is difficult to treat and is mostly treated with chemotherapy, with the addition of drugs like pertuzumab and trastuzumab [3]. \\u0026nbsp;Comprehending the molecular reactions to chemotherapy is essential, particularly as the swift advancement of targeted treatments has led to a reexamination of conventional approaches. FDA-approved CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, have demonstrated potential for ER+/HER2-negative cases., evidence suggests they induce replication stress, which may influence resistance to PARP inhibitors,this has spurred interest in combining CDK4/6 inhibitors with PARP inhibitors, leading to RiboComb therapy to overcome resistance in endocrine and CDK4/6 treatments[4]\\u003c/p\\u003e\\n\\u003ch3\\u003e1.1. Background and Rationale\\u003c/h3\\u003e\\n\\u003cp\\u003eBreast cancer is currently the most commonly diagnosed cancer globally, a trend that is largely influenced by demographic changes favoring an aging population, to improve diagnostic precision and therapeutic strategies, various molecular subtypes of the disease are classified according to hormone receptor status\\u0026nbsp;[5]. Patients who present with the hormone receptor-positive/HER2-negative metastatic subtype typically receive endocrine therapies, such as aromatase inhibitors, nevertheless, the emergence of resistance to these treatments often leads to tumor recurrence and disease progression, necessitating the exploration of alternative therapeutic options, in this regard, CDK inhibitors have come to the forefront as effective agents that target these resistance mechanisms\\u0026nbsp;[6]. A comprehensive understanding of the underlying mechanisms of resistance is essential for the formulation of successful treatment plans, specifically, CDK4/6 inhibitors have attracted considerable attention due to their role in promoting cell cycle progression and mitigating resistance through the phosphorylation of retinoblastoma protein\\u0026nbsp;[7]. Clinical trial data reveals that the application of CDK4/6 inhibitors is correlated with enhanced progression-free survival (PFS), highlighting their importance in first-line therapies when used in conjunction with endocrine treatments. Furthermore, these inhibitors display a favorable safety profile, presenting no significant increase in adverse effects relative to placebo, which further reinforces their inclusion in treatment protocols. [8]\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003eThe phosphoinositide 3 kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) signaling pathway is crucial in the advancement, recurrence, and metastasis of hormone receptor-positive/HER2-negative breast cancer, this pathway is responsible for the regulation of vital cellular functions, including proliferation and metabolism, by facilitating the communication of signals from growth factor receptors. This signaling cascade promotes processes such as cell cycle progression, protein synthesis, and glucose metabolism\\u0026nbsp;[9] . About 40% to 50% of cancer cells show pathway activation issues. New inhibitors targeting this signaling cascade have demonstrated promising results for patients previously treated with CDK4/6 inhibitors. However, no direct comparative trials exist to assess their efficacy, and insights from indirect studies remain unclear \\u0026nbsp;[10]\\u003c/p\\u003e\\n\\u003ch3\\u003e1.2. Significance of the Study\\u003c/h3\\u003e\\n\\u003cp\\u003eThis research examines the efficacy of CDK4/6 inhibitors versus traditional chemotherapy within a real-world framework, focusing on both treatment outcomes and side effects. Furthermore, the study seeks to pinpoint variables that might forecast or elucidate variations in treatment responses on a patient-by-patient basis. Variables associated with poorer treatment outcomes could potentially be addressed by modifying the treatment regimen or integrating supplementary medications.\\u003c/p\\u003e\\n\\u003cp\\u003eThe CDK4/6 inhibitors for breast cancer, including palbociclib, ribociclib, and abemaciclib, are oral medications targeting key molecular components that regulate the cell cycle in cancer cells, high-quality clinical trials show these inhibitors improve overall survival in postmenopausal women with hormone receptor-positive metastatic breast cancer, offering better outcomes than traditional endocrine therapy in initial treatments. \\u0026nbsp;[11]\\u003c/p\\u003e\\n\\u003cp\\u003eA retrospective observational study evaluated CDK4/6 inhibitors versus standard chemotherapy in Bavarian women, showing a statistically significant improvement in progression-free survival,this finding is crucial, highlighting the potential of CDK4/6 inhibitors to provide a more targeted approach, thereby enhancing treatment outcomes for metastatic breast cancer patients [12]. Results indicated a notable progression-free survival benefit for those on CDK inhibitors over conventional treatments, advocating further research into their long-term advantages and impact on quality of life, while also reflecting patient demographics and treatment scenarios from 2000 to 2019 [13]\\u003c/p\\u003e\"},{\"header\":\"2. Metastatic Breast Cancer (MBC)\",\"content\":\"\\u003cp\\u003eMetastatic breast cancer (MBC) is an incurable condition, prompting a shift from prolonging survival to managing it as a chronic disease, treatments like palliative radiotherapy and MRgFUS are used to relieve symptoms, and improve the quality of life for patients\\u0026nbsp;[14] Analyzing the pathways of metastatic breast cancer (MBC) progression and the effect of targeted therapies on outcomes is essential. Treatment strategies depend on clinical variables, healthcare resource limitations, and patient preferences. Despite efforts to improve care, survival rates for MBC patients have seen minimal improvement\\u0026nbsp;[1].\\u0026nbsp; Systemic therapies often yield poor outcomes, with only a few patients achieving lasting benefits, limited clinical trial data hampers understanding of treatment effectiveness, current research focuses on comparing CDK inhibitors and traditional chemotherapy across various MBC settings to address gaps in the literature\\u0026nbsp;[15].\\u003c/p\\u003e\\n\\u003ch3\\u003e2.1. Epidemiology and Incidence\\u003c/h3\\u003e\\n\\u003cp\\u003eBreast cancer (BC) stands out as the most common type of cancer among women and the second most deadly, as the fatality of lung cancer in women continues to decrease, in recent years BC has particularly increased compared to other cancers\\u0026nbsp;[16]. In the US, the general rate of cancer occurrence in women (females) is much lower than in males but, unfortunately, this disease is the second most deadly in them. Over the last two decades, relatively there has been a greater decline in the mortality associated with BC thanks to advancements in cancer research, importantly, race, behavior, and demographic factors hugely influence disease epidemiology\\u0026nbsp;[17]\\u003c/p\\u003e\\n\\u003cp\\u003eBreast cancer incidence is lower in women under 40, increasing after 45, about one in eight women will be diagnosed, with variations by ethnicity, non-Hispanic women in the U.S. have a higher rate, while Asian-Americans have lower rates, African-American women experience the highest mortality, possibly due to delayed diagnoses. Hormone replacement therapy (HRT), especially with estrogen and progestin for six to seven years, is associated with a higher incidence, potentially doubling breast cancer risk\\u0026nbsp;[18]\\u003c/p\\u003e\\n\\u003cp\\u003eAlcohol consumption, obesity, familial predisposition, and early radiation exposure are significant factors in developing breast cancer, women with one family member diagnosed have a slightly elevated risk, but the risk more than doubles if the mother is affected or three or more close relatives have the condition, those with a family history are more likely to be diagnosed\\u0026nbsp;[19]. Recent genetics developments highlight hereditary risks linked to BRCA1 and BRCA2 genes. BRCA1 mutations account for 55-65% of triple-negative breast tumors, while BRCA2 mutations relate to hormone receptor-positive cancers. About 2.5% of women diagnosed with breast cancer before 40 have these mutations\\u0026nbsp;[20]\\u003c/p\\u003e\\n\\u003ch3\\u003e2.2. Pathophysiology\\u003c/h3\\u003e\\n\\u003cp\\u003eMetastasis is a key characteristic of malignant tumors and a major contributor to cancer mortality. In recent decades, research on the mechanisms of metastasis has intensified, reflecting its significance in oncology, identifying genes linked to antitumor metastasis has advanced this research area. Understanding the processes behind tumor metastasis could lead to new molecular therapy targets and treatment strategies, future oncology research must improve the management of tumor metastasis at all stages, from diagnosis to personalized therapy approaches\\u0026nbsp;[21]\\u003c/p\\u003e\\n\\u003cp\\u003eBreast cancer (BC) ranks as the second most frequent malignant tumor worldwide, after lung cancer, significantly impacting women\\u0026apos;s health, approximately 40% of luminal BC cases feature mutations in the PIK3CA gene, which contributes to endocrine therapy resistance and reduces Cyclin Dependent Kinase 4/6 inhibitors\\u0026apos; effectiveness\\u0026nbsp;[22]. The median progression-free survival (PFS) rates are 26 months for monotherapy and 38 months for combination therapy. However, some patients may not respond or may show decreased clinical benefits, emphasizing the need for predictive biomarkers. Advancements in molecular biology, genetics, and immunology have enhanced our understanding of breast cancer (BC) progression and facilitated the creation of targeted therapies based on specific genetic alterations\\u0026nbsp;[23]\\u003c/p\\u003e\\n\\u003ch3\\u003e2.3. Current Treatment Landscape\\u003c/h3\\u003e\\n\\u003cp\\u003eMetastatic breast cancers (MBC) are recognized as the most advanced stage of breast cancer, attracting considerable global research efforts,Significant advancements have led to the development of targeted therapies, notably cyclin dependent kinase 4/6 inhibitors (CDK4/6i), which have revolutionized MBC treatments, enhancing progression-free survival alongside endocrine therapy (ET) since the introduction of Palbociclib in 2015\\u0026nbsp;[24]. Nonetheless, patients resistant or intolerant to ET still need chemotherapy, and the issue of resistance to CDK4/6i remains unsolved\\u0026nbsp;[25] .This study aimed to clarify treatment strategies for MBC patients based on endocrine sensitivity\\u0026mdash;categorized as endocrine sensitivity (ETS) and endocrine therapy resistance (ETR)\\u0026mdash;to improve overall survival (OS) rates. A Network Meta-Analysis was conducted using comprehensive existing data\\u0026nbsp;[26]Results indicated that combining CDK4/6i with fulvestrant 500 mg was most effective for ETS patients, while chemotherapy was better for ETR patients, thus, tailoring treatment strategies based on endocrine sensitivity profiles is recommended to enhance the effectiveness of CDK inhibitors and chemotherapy for metastatic breast cancer\\u0026nbsp;[27]\\u003c/p\\u003e\\n\\u003cp\\u003eCell cycle dysregulation leading to sustained cellular proliferation is a hallmark of cancer. In luminal mammary epithelium cancers, key regulators are D-type cyclins and CDK4/6. CDK4/6, serine/threonine kinases, form a complex with cyclin D, impacting retinoblastoma protein (Rb) activity\\u0026nbsp;[28]. The hyper-phosphorylation of Rb by cyclin D and CDK4/6 is essential for binding the E2F transcription factor, aiding the transition from G1 to S phase for DNA replication. Compromised Rb function leads to deregulated cell cycle progression, presenting a chance for targeted therapeutic interventions\\u0026nbsp;[29].\\u003c/p\\u003e\\n\\u003cp\\u003eAn analytical examination of the therapeutic pathway reveals CDK4/6 inhibitors, which block CDK4/6 activity while sparing other kinases,they are effective for luminal and HER2-amplified breast cancer subtypes, showing advancements in clinical use, three compounds are authorized with endocrine therapy for HR-positive/HER2-negative breast cancer [30]. This class exhibits cytostatic effects in neoadjuvant/adjuvant treatments but cytotoxic properties in metastatic cases, research focuses on tumor characteristics that dictate responsiveness, notably the p16 protein\\u0026apos;s influence on therapeutic response [31]\\u003c/p\\u003e\"},{\"header\":\"4. Preclinical Studies\",\"content\":\"\\u003cp\\u003eIntense advertising has promoted orally administered CDK inhibitors over traditional intravenous chemotherapy, but the data does not fully confirm these claims. While current chemotherapy offers similar efficacy to CDK inhibitors, its outcomes are frequently poorer[32] .The small benefit\\u0026mdash;a slight recovery increase in some Metastatic Breast Cancer patients\\u0026mdash;relates to specific medication rather than a genuine advantage, this is tied to chemotherapy\\u0026apos;s decreasing effectiveness, a trend not observed with CDK inhibitors, furthermore, financial data for chemotherapy is available in U.S. dollars, while data for CDK inhibitors is lacking, raising concerns about their purported benefits\\u0026nbsp;[33]. A clinical study utilizing Real-World Data on 893 Metastatic Breast Cancer patients treated with CDK 4-6 inhibitors explored treatment resistance, assessing the relationship between clinicopathological factors and survival, the study employed various statistical methods, revealing that Ac-Poor disease may hinder the effectiveness of CDK 4/6 inhibitors and lower survival rates, an artificial neural network was also created to predict individual patient treatment responses.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003ch3\\u003e4.1. In Vitro Studies\\u003c/h3\\u003e\\n\\u003cp\\u003eThe research explores a rapid method to induce apoptosis in tumor cells through \\u0026gamma;-irradiation, 5-fluorouracil, doxorubicin, paclitaxel, and other genotoxic agents, focusing on growth inhibition linked to p53/Mdm-2 in both p53-deficient and regular breast cancer (BC) cells[34] .Traditional invasive methods disrupted the IPTG gene system in \\u0026quot;suicide gene therapy,\\u0026quot; while this study highlights IPTG systems with dominant antisense RNAs that degrade target genes, customizable inducible vectors can enhance pro-apoptotic effects by modifying promoter strength, boosting cytotoxicity in combination therapies. Key findings indicate improved progression-free survival for both endocrine-sensitive and resistant BC patients using CDK4/6 inhibitors\\u0026nbsp;[35]. Recognizing resistance mechanisms is crucial, as standard hormone receptor-positive BC treatments involve hormone therapy alongside CDK4/6 inhibitors, which gained approval after successful phase III trials such as PALOMA-3\\u0026nbsp;[36] . Prominent inhibitors include palbociclib, ribociclib, and abemaciclib, including those targeting p16, p21, p27, and p57. Palbociclib and ribociclib act as selective ATP-binding inhibitors for CDK4 and CDK6, with ribociclib\\u0026apos;s efficacy unaffected by food intake,resistance mechanisms could involve reactivated Rb through p38 and JNK pathways, a shortened G1 phase, increased CDK6 expression, and mutations in Rb/p16, prompting cell cycle reentry\\u0026nbsp;[37]\\u003c/p\\u003e\\n\\u003ch3\\u003e4.2. In Vivo Studies\\u003c/h3\\u003e\\n\\u003cp\\u003eThe primary endpoint of progression-free survival (PFS) in the phase 3 PEARL study indicated limited effectiveness of palbociclib combined with endocrine therapy, highlighted by borderline p-values. Researchers aimed for a deeper understanding through comparative analyses\\u0026nbsp;[38] .Treatment preferences linked to endocrine-gene testing methodology (EGTM) showed differences among populations, leading to group comparisons to address imbalances, the analysis included intrinsic subtypes to examine treatment subgroups more closely, evaluations did not show significant improvements in PFS with the cyclin-dependent kinase inhibitor (CDKi)\\u0026nbsp;[39]. Additionally, prior progression-free interval (PFI) was a key prognostic factor for PFS, regardless of the treatment used\\u0026nbsp;[40]\\u003c/p\\u003e\\n\\u003cp\\u003eThe conclusion of relationships offers valuable insights for future interactions, particularly for metastatic breast cancer patients and their oncologists [41]. Ending treatment requires an adjustment, as shared exhaustion affects these therapeutic alliances, this research analyzed post-CDK4/6 inhibitor treatment relationships by examining 86 patients, focusing on oncologists\\u0026apos; satisfaction and emotional responses to metastasis [42] .\\u003c/p\\u003e\"},{\"header\":\"5. Clinical Trials\",\"content\":\"\\u003cp\\u003eBreast cancer is the most common malignancy globally, with 2.3 million new cases in 2020, primarily affecting women, About 70-80% of these cases are hormone receptor-positive tumors, which may be HER2 positive or negative, this classification aids in targeted diagnostics and therapies\\u0026nbsp;[5]. For hormone receptor-positive/HER2-negative tumors, standard treatment is endocrine therapy (ET) using aromatase inhibitors and selective estrogen receptor modulators, however, resistance to ET presents challenges for future treatments, recent trials have highlighted alpelisib, a PIK3CA inhibitor, as a promising option when paired with fulvestrant\\u0026nbsp;[43]. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have also changed the treatment landscape, with abemaciclib being the third approved option,in light of ET resistance, multiple chemotherapy agents, including nab-paclitaxel and eribulin, are used in metastatic cases following earlier \\u0026nbsp;treatments\\u0026nbsp;[44]\\u003c/p\\u003e\\n\\u003cp\\u003eThis article throws a comparative analysis between two special existing scientific treatments options for patients with the hormone receptor-positive/HER2-negative subtype of metastatic breast cancer who have failed ET and cancer have visited one or two lines of aminoacyl endocrine therapy, of which one is a targeted therapeutic agent such as CDK4/6 inhibitors (CDK4/6i) or PI3K/AKT/mTOR inhibitors (PAMi). The special agents under assessment are palbociclib plus endocrine treatment, and concomitant EVE plus exemestane. Due to the scarcity of obtainable evidence, a network meta-evaluation (NMA) built on posted randomized managed trials (RCTs) had not been conducted but it could make a contribution to understanding how to weigh different treatment choices. At the currently final censoring date, a total of 7 RCTs were recognized: 3 RCTs compared CDK4/6i with ET, 2 RCTs assessed PAMi in comparison to ET.\\u003c/p\\u003e\\n\\u003ch3\\u003e5.1. Design and Methodology\\u003c/h3\\u003e\\n\\u003cp\\u003eEpidemiological research shows that cyclin-dependent kinase inhibitors (CDKis) outperform standard chemotherapy in estrogen receptor-positive/HER2-negative (ER+/HER2\\u0026ndash;) metastatic breast cancer (MBC), evidenced by lower tumor proliferation and secondary lesions. However, a lack of randomized controlled trials (RCTs) limits definitive assessments. An ongoing study seeks to compare CDKis with conventional chemotherapy, focusing on tumor proliferation rates and secondary lesions via network meta-analysis. Eligible participants include those with AHR+/HER2\\u0026ndash; status, newly diagnosed or with metastatic recurrence, and an ECOG PS score of 0 to 2, with measurable lesions as per RECIST 1.1 criteria, regardless of the timing of metastatic diagnosis.\\u003c/p\\u003e\\n\\u003cp\\u003eConventional chemotherapy and emetic therapy were excluded from this analysis, while earlier interventions like local/systemic treatments and endocrine therapies were deemed irrelevant in some studies. Due to potential publication bias regarding secondary lesions, a prospective registration process was established, even though most studies involving CDK inhibitors (CDKi) had ended by November 2020. For pharmacokinetic-pharmacodynamic (PK-PD) analysis, tools PsN 5.1.0, PkPDerr 0.5.7, and SPL-conformed AUTAs/APTAs were utilized. Key efficacy metrics included the relative change in the sum of the longest diameters (SLD) as a percentage and the dose-response relationship of ribociclib, with a target effect size reduction of 2.5 for primary lesion activity in metastatic breast cancer (MBC) compared to the pooled mean treatment level (MTL).\\u003c/p\\u003e\\n\\u003ch3\\u003e5.2. Key Findings\\u003c/h3\\u003e\\n\\u003cp\\u003eA total of 47 randomized clinical trials were included in this network meta-analysis (NMA) after applying eligibility criteria, involving 28,106 patients. Two studies evaluated CDK4/6 inhibitor treatments, and two focused on chemotherapy alternatives. Additionally, advanced endocrine therapies were analyzed, represented by one chemotherapy-based study, four standalone endocrine monotherapy studies, and fifteen studies exploring combinations of endocrine therapies, with or without other pharmacological agents. All treatments were categorized under the intervention arm of the analysis.\\u003c/p\\u003e\\n\\u003cp\\u003eThe patterns of spread resembling a \\u0026quot;crown-like\\u0026quot; formation observed on digital breast tomosynthesis (DBT) mammograms are often found to exhibit clustering tendencies, which correlate closely with the degree of malignancy. This clustering phenomenon in DBT presents an opportunity to derive a meaningful descriptor of breast density distribution that could enhance breast health evaluations. To this end, a novel metric has been introduced to quantify the occurrence of discrete breast density clusters identified in DBT mammograms; this metric is termed the cluster density metric.\\u003c/p\\u003e\\n\\u003cp\\u003eThe cluster density metric is highly sensitive to the quantity of density clusters in digital breast tomosynthesis (DBT) mammograms, showing weak correlation with volumetric breast density on an area-based scale. Breast density often concentrates into larger high-density regions, leading to \\u0026ldquo;crown-like\\u0026rdquo; false positives. Cluster characteristics are reliable indicators of breast cancer risk, with height variation in cluster pairs indicating nearly double the odds of cancer risk later in life.\\u003c/p\\u003e\"},{\"header\":\"6. Efficacy Comparison\",\"content\":\"\\u003cp\\u003eRecent developments have seen the global regulatory endorsement of three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i): abemaciclib, palbociclib, and ribociclib. Although clinical trials indicate comparable outcomes regarding progression-free survival (PFS) across these agents, notable discrepancies arise in the overall survival (OS) metrics\\u0026nbsp;[45]. While individual evaluations are available, a detailed comparative analysis that centers on OS, safety, and tolerability is imperative. This need is underscored by the fact that abemaciclib permits elevated doses in monotherapy and offers the advantage of continuous administration unencumbered by dietary restrictions. [46]\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003eMetastatic Breast Cancer (MBC) represents an advanced stage with a poor prognosis. Endocrine therapy is the main treatment, often involving CDK4/6 inhibitors, although only about 20% of patients benefit\\u0026nbsp;[2]. For advanced estrogen receptor-positive (ER+)/HER2-negative mBC, common treatments include anti-estrogens and endocrine therapies. Recent strategies highlight early intervention and better combinations, particularly with CDK4/6 inhibitors, proving effective in postmenopausal patients. Nonetheless, treatment resistance poses a significant challenge, resulting in high morbidity and mortality\\u0026nbsp;[47]. Addressing resistance leads to uncertainties about the best therapies for varied clinical scenarios. This study reviews endocrine therapy regimens, ranking them by outcomes like progression-free survival (PFS) and overall survival (OS) for HR+/HER2- mBC patients, based on their endocrinal treatment response\\u0026nbsp;[48] .The estrogen receptor (ER) signaling pathway is crucial for HR+ breast cancer, requiring strategies that use endocrine therapy (ET) to restrict estrogen receptor binding [49] .\\u003c/p\\u003e\\n\\u003ch3\\u003e6.1. Overall Response Rate\\u003c/h3\\u003e\\n\\u003cp\\u003eThe research, supported by industry funding, evaluated the efficacy of targeted therapies by contrasting the outcomes of CDK inhibitors combined with endocrine treatment against a placebo, with a primary focus on postmenopausal patients.\\u0026nbsp;[50].The PALOMA-2 trial encompassed both pre- and postmenopausal women; however, the primary emphasis was placed on participants who were receiving endocrine therapy for metastatic disease for the first time, significant enhancements in progression-free survival (PFS) and overall response rates were documented.\\u0026nbsp;[51]. The primary measure was the \\u0026quot;24-week clinical benefit rate (CBR)\\u0026quot; of CDK 4/6 inhibitors and aromatase inhibitors versus chemotherapy for hormone receptor-positive metastatic breast cancer in postmenopausal women after non-steroidal aromatase inhibitor therapy\\u0026nbsp;[52]. PALOMA-2 showed significant outcomes, but FALCON and MONARCH-3 did not achieve significance, displaying broad confidence intervals.\\u0026nbsp;[53]\\u003c/p\\u003e\\n\\u003ch3\\u003e6.2. Progression-Free Survival\\u003c/h3\\u003e\\n\\u003cp\\u003eProgression-free survival (PFS) is a crucial endpoint in cancer therapy trials, marking the time from treatment initiation to cancer progression\\u0026nbsp;[54]. This metric is valuable for addressing the complexities of patient-reported outcomes (PROs), such as quality of life. Currently, the role of PFS in predicting overall survival is under scrutiny, considering demographic, clinical factors, and various statistical methods, however, analyses focusing on individual patient data are often insufficient, potentially missing important predictive factors. Improving research methodologies requires a patient-centered approach to drug administration, incorporating historical treatment data and prescription practices\\u0026nbsp;[55]. It\\u0026apos;s also vital to investigate treatment-related and drug-specific variables Such customized models can reveal the biological mechanisms behind disease progression,a relevant study included 316 women with metastatic breast cancer (MBC) treated with a CDK4/6 inhibitor\\u0026nbsp;[56]\\u003c/p\\u003e\\n\\u003ch3\\u003e6.3. Overall Survival\\u003c/h3\\u003e\\n\\u003cp\\u003eThe comparison shows that abemaciclib with endocrine therapy (ET) significantly reduces mortality risk compared to most treatments, except pembrolizumab + ET (HR 0.74, 95% CrI 0.60-0.90), no significant overall survival differences were found with paclitaxel or gefitinib + vinorelbine, but progression-free survival (PFS) showed notable differences due to drug toxicity and dosage. In the network meta-analysis, abemaciclib + ET had a 35-fold increase in hazard ratios, with HR 0.77, 95% CrI 0.57-1.02, especially versus placebo + ET, confirming earlier findings [46], i.e. a statistically significant (trend) effect was found for abemaciclib for the OS. Overall, there were 1,587 participants from 15 RCTs for the relative effectiveness defined as the primary endpoints of the time to the failure for each of the considered treatments [57]. Remarkably, there were consistent results across a variety of effectiveness measures that showed the comparison of efficacy of the considered treatments, first, each drug showed a statistically significant difference in PFS (progression-free survival) compared to placebo + ET . For abemaciclib + ET and palbociclib + ET (treatment strategy 1), these drugs showed a 73% and 60% reduction in the hazard of failure compared to placebo + ET, respectively (PFS R 0.27, 95% CrI 0.20-0.36; PFS R 0.40, 95% CrI 0.32-0.50). For ribociclib + ET (treatment strategy 2), there was a 53% reduction in the hazard of failure compared to placebo in a case where, respectively, they were given with letrozole or Faslodex (PFS R 0.47, 95% CrI 0.33-0.64; PFS R 0.53, 95% CrI 0.47-0.67). In summary, the effectiveness was found on the treatment strategy of the CDK4\\u0026amp;6 inhibitor with endocrine therapy, which significantly prolongs the failure time of the metastatic breast cancer treatment. On the other hand, these drugs were not significantly different compared to the comparator drugs cetuximab + FOLFIRI, cisplatin + paclitaxel, paclitaxel, vinca alkaloids, or placebo in combination with endocrine therapy.\\u003c/p\\u003e\"},{\"header\":\"7. Safety Profile\",\"content\":\"\\u003cp\\u003eThe safety profile of CDK 4/6 inhibitors will be assessed against conventional chemotherapy using registration trial data. This aims to clarify adverse events linked to CDK 4/6i for toxicity comparison\\u0026nbsp;[58]. The analysis will include angiogenesis inhibitors as comparable treatments. Initially, systemic treatment-related AEs will be assessed, followed by a review of special treatments and phase II and III clinical trials using network strategies.\\u003c/p\\u003e\\n\\u003cp\\u003eIn drug registration studies for experimental medications, attention focuses on evaluating toxicity profiles compared to conventional treatments, findings are published to provide healthcare professionals with insights into toxicity management. Since palbociclib\\u0026apos;s approval in 2015 for metastatic hormone receptor-positive breast cancer based on the PALOMA trials, CDK 4/6 inhibitors have become standard options for treatment. A systematic analysis will compare adverse events in randomized trials of these inhibitors (palbociclib, ribociclib, abemaciclib) with endocrine therapy, as well as conventional chemotherapy, through direct comparative studies and network analyses of angiogenic inhibitors\\u0026nbsp;[59]\\u003c/p\\u003e\\n\\u003cp\\u003eSixty-seven qualitative safety evaluations from randomized phase II and III trials were analyzed, focusing on the effectiveness and toxicity of CDK 4/6 inhibitors and angiogenic inhibitors, this review involved 49 studies, with 26 on CDK 4/6 and 23 on angiogenic inhibitors, covering breast cancer treatments and detailing safety outcomes and toxicities considered. [60]\\u0026nbsp;\\u003c/p\\u003e\\n\\u003ch3\\u003e7.1. Adverse Events Comparison\\u003c/h3\\u003e\\n\\u003cp\\u003eA recent study compared CDK inhibitors with conventional chemotherapy in metastatic breast cancer patients. It found no significant differences in grade 3 adverse events between treatments. However, CDK inhibitors showed a lower incidence of grade 1\\u0026ndash;2 adverse events, particularly diarrhea, nausea, stomatitis, and anemia. Patients on CDK inhibitors were less likely to stop treatment due to adverse effects, especially grade 3 events. The study gathered data on cancer burdens and late-line therapy metrics. With a median age for reported toxicities at 70 years, the study highlighted the importance of evaluating both efficacy and tolerability, particularly since CDK inhibitor treatment may exceed two years.\\u003c/p\\u003e\\n\\u003ch3\\u003e7.2. Quality of Life\\u003c/h3\\u003e\\n\\u003cp\\u003ePatients with advanced hormone receptor-positive breast cancer often face prolonged disease with recurrent metastases, necessitating effective and tolerable treatment regimens. Health-related quality of life is essential for evaluating treatment outcomes. This research analyzes quality of life in patients treated with ARIMA versus those receiving capecitabine alone or capecitabine combined with ARIMA, alongside patients unable to use capecitabine. The aim is to assess whether this innovative therapy enhances quality of life compared to existing treatments, utilizing instruments from the European Organization for Research and Treatment of Cancer for evaluations. This study marks the first prospective randomized quality of life analysis in this context.\\u003c/p\\u003e\\n\\u003cp\\u003eThe intervention focuses on improving progression-free survival and quality of life for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. It aims to provide randomized controlled trial evidence for treatment effectiveness. Patient-Reported Outcomes (PRO) are vital for evaluating new treatments, helping manage side effects and enhance quality of life. Combining CDK4/6 inhibitors with endocrine therapy improves progression-free survival for those not previously treated. Assessing palbociclib with hormonal therapy against gonadotropin-releasing hormone agonist plus exemestane and capecitabine is essential for this group.\\u003c/p\\u003e\"},{\"header\":\"8. Resistance Mechanisms\",\"content\":\"\\u003cp\\u003eThe G1/S checkpoint is vital in cell cycle progression, mainly regulated by cyclin-dependent kinases (CDKs), which also affect transcription and development,CDK dysregulation is associated with various cancers, leading to the creation of CDK4/6 inhibitors for advanced malignancies\\u0026nbsp;[61]Pitolisant can detach the coactivator cycle box protein from Smad3. Several natural compounds have been studied for breast cancer treatment. Research shows C-DIM12 has limited anti-cancer effects among garcinol derivatives. Lcdm1thorin-A1 enhances MDA-MB-231 cell sensitivity to vinblastine, indicating that danferolbin-DIRAs might offer new treatment options. Sophocarpine, a tetracyclic quinazolinone alkaloid, exhibits pharmacological effects that could help address brain ischemia and various cancers. [62]\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003eThe strategic interruption of the cell cycle at the G1/S phase using CDK4/6 inhibitors proves effective for eradicating cancer cells, benefitting many patients. However, breast cancer cells can later re-establish and enhance proliferation. Research shows that four major pathways\\u0026mdash;MYC, TGF-beta, RAS, CCND1, RB, and KRAS\\u0026mdash;interact with mutations in the CDKI pathway, undermining targeted chemotherapy efficacy. This framework unveils novel signaling routes for cancer growth. Moreover, human breast epithelial cells undergo a multistep transformation process\\u0026nbsp;[13]Resistance to CDK inhibitors is complex, with CDK4/6 levels potentially affecting drug sensitivity, as seen with LEE013 and HCC1500 cell lines, and transient gene repression leading to reduced CDK4A protein levels, delaying responses[63] .\\u003c/p\\u003e\\n\\u003ch3\\u003e8.1. CDK Inhibitor Resistance\\u003c/h3\\u003e\\n\\u003cp\\u003eInitial observations regarding the efficacy of CDK inhibitors reveal a spectrum of responses, with distinct resistance mechanisms correlated with specific biomarkers,a significant number of patients with luminal subtype breast cancer exhibit either pre-existing or acquired resistance to CDK4/6 inhibitors\\u0026nbsp;[64]. The phosphorylation status of Rb is observed to elevate following chemotherapy administration, which subsequently influences the sensitivity to CDK4/6 inhibition\\u0026nbsp;[65]. Notably, only a limited percentage of breast cancer cell lines that are sensitive to treatment demonstrate heightened Rb phosphorylation post-cytotoxic exposure, a phenomenon that may be attributed to post-translational modifications. Results derived from reverse phase protein array (RPPA) analyses indicate that cyclins E2, D1, and D3 could play critical roles in mediating resistance, particularly highlighting the impact of N-terminal phosphorylation of Cyclin D1 upon its interaction with CDK4\\u0026nbsp;[66]. Amplification or overexpression of CCND1 has been associated with the emergence of resistance to palbociclib, typically manifested within an approximate timeframe of eight weeks. While the overexpression of CCND1 serves as a prevalent mechanism for resistance, it cannot solely determine sensitivity to CDK inhibitors\\u0026nbsp;[67]. Patients classified as Luminal A frequently demonstrate responsiveness to CDK4/6 inhibitors despite the absence of CCND1 amplification. Thus, pinpointing these patients is vital for the optimization of treatment strategies, as a comprehensive understanding of the resistance profiles will enhance the effectiveness of single-agent CDK inhibitor therapies[68]\\u003c/p\\u003e\\n\\u003ch3\\u003e8.2. Chemotherapy Resistance\\u003c/h3\\u003e\\n\\u003cp\\u003eResistance to trastuzumab (Tmab) in breast cancer patients arises from overexpressed HER2 p95, high IGF-1 levels, HER2 mutations, and a tumor microenvironment (TME) dominated by Tregs and active tumor stem cells [69]. The TME exacerbates resistance via the PD-1/PD-L1 and CTLA-4 pathways,CDK4/6 inhibitors target immunosuppression pathways, enhancing immune cell infiltration and reducing fibroblast-mediated suppression [70] .Chemotherapy is the main treatment for metastatic breast cancer, especially for HR-negative and HER2-negative cases. Current second-line CDK4/6 inhibitors haven\\u0026apos;t shown better results than established treatments. In contrast, Mtb monotherapy has an impressive ORR of 34.0% and a CBR of 68.6%, outperforming immuno-oncology therapies. It also offers a median PFS of 15.0 months, highlighting its viability in treatment options [71] .The FDA\\u0026apos;s fast-tracked approval of Mtblazi for Mtb-resistant patients offers promising new treatment options.\\u0026nbsp;\\u003c/p\\u003e\"},{\"header\":\"9. Combination Therapy Approaches\",\"content\":\"\\u003cp\\u003eIn recent decades, there has been a rise in adaptive mutations within tumor cells of patients undergoing endocrine therapy\\u0026nbsp;[72]. Many metastatic lesions show the ability to evade or resist endocrine inhibitors that affect proliferation and survival pathways. Although chemotherapy remains a key treatment, its benefits must be weighed against potential toxicity risks\\u0026nbsp;[73]. This highlights the need for effective targeted agents that can operate alone or with endocrine therapy, while considering chemotherapy to improve tolerability\\u0026nbsp;[74]. To date, few reports have compared the efficacy of these agents in hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients responsive to endocrine treatment using a common control group via network meta-analysis\\u0026nbsp;[75]. Therefore, this study aims for a systematic review and network meta-analysis (NMA) to evaluate efficacy outcomes of progression-free survival (PFS) and overall survival (OS).\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003eIn the present study, the random-effects NMA model of frequentist frameworks was conducted to integrate direct and indirect evidence to compare the relative efficacies of different ET-based regimens for HR+/HER2- mBC patients with different endocrine sensitivity statuses in terms of PFS and OS. A total of 47 randomized clinical trials published between January 2001 and December 2020 were identified that included 32 different ET-based regimens involving 42,827 patients.\\u003c/p\\u003e\\n\\u003ch3\\u003e9.1. Rationale for Combination Therapy\\u003c/h3\\u003e\\n\\u003cp\\u003eConventional chemotherapy remains a standard treatment for breast cancer, though it has lower therapeutic indices compared to newer targeted drugs in metastatic cases. Palbociclib, a CDK4 and CDK6 inhibitor, has transformed the management of HR-positive breast cancer. However, combining palbociclib with cytotoxic agents hasn\\u0026apos;t improved efficacy in various BC culture systems, highlighting the need for more research into the effectiveness of CDK4/6 inhibitors with chemotherapy agents. [76]\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003eHerceptin\\u0026reg;, combined with Tykerb\\u0026reg; and Perjeta\\u0026reg;, is widely acknowledged for treating HER2-positive breast cancer (BC), however, survival outcomes for patients with HER2-positive tumors achieving complete response remain inadequate. Adding palbociclib, a CDK4/6 inhibitor, to Herceptin\\u0026reg;, lapatinib, or Tykerb\\u0026reg; may enhance therapeutic efficacy. Yet, recent safety concerns about certain non-curative drugs necessitate clinician caution in using these treatments\\u0026nbsp;[77]\\u003c/p\\u003e\\n\\u003ch3\\u003e9.2. Clinical Evidence\\u003c/h3\\u003e\\n\\u003cp\\u003eMetastatic breast cancer (MBC) is an unstoppable phase of breast cancer (BC) and greatly affects the survival of affected persons. Up to 5% of all cancer deaths are due to metastasizing BC annually. Therefore, it becomes necessary to avail the best treatment that will act effectively. The aim of this research is to compare the effectiveness of cyclin-dependent kinase (CDK) inhibitors and conventional chemotherapy in terms of the hazard ratio of progression-free survival (HR-PFS).\\u003c/p\\u003e\\n\\u003cp\\u003eThe research examines three CDK inhibitors: palbociclib, abemaciclib, and ribociclib, focusing on their effectiveness when used alone and with other therapies. An open-label, non-randomized methodology was used, revealing that CDK4/6 inhibitors perform better than traditional chemotherapy. However, no significant difference in patient outcomes was found when CDK4/6 inhibitors were combined with aromatase inhibitors. Additionally, cyclin E1 expression levels were more favorable with CDK4/6 inhibitors than with aromatase inhibitors or chemotherapy. The study centers on metastatic breast cancer (BC), highlighting 191,410 new cases and 43,600 deaths. Its primary goal is to compare the efficacy of CDK inhibitors against chemotherapy in treating metastatic breast cancer patients.\\u003c/p\\u003e\\n\\u003cp\\u003eResearch focused on optimizing treatments to inhibit and eradicate cancer cells is growing. Significant efforts have been dedicated to developing targeted therapies for breast cancer patients classified as M1. However, the effectiveness of these treatments is limited by genetic variability and differing expressions among patients during treatment. Additionally, there\\u0026apos;s no evidence that sequential treatment regimens are better than standalone approaches.\\u003c/p\\u003e\"},{\"header\":\"10. Future Directions and Emerging Therapies\",\"content\":\"\\u003cp\\u003eBreast cancer is the most common malignant tumor in women, with about 70% diagnosed early. However, nearly a third progress to metastatic breast cancer (mBC). HR+/HER2-negative breast cancer accounts for 65-70% of mBC and lacks ERBB2 overexpression while expressing estrogen or progesterone receptors. These tumors do not respond to HER-targeted treatments but are sensitive to endocrine therapy affecting the estrogen signaling pathway. Treatments include estrogen inhibitors and aromatase inhibitors, but resistance can develop, leading advanced HR+ tumors to require CDK4/6 inhibitors for better therapy efficacy. [49]\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003eTumor progression frequently occurs, with 30% of US patients experiencing distant metastases. Studies indicate that RB1 and ESR1 gene fusions are linked to CDK4/6i resistance in luminal breast cancers. The various genetic causes of therapy resistance highlight the intrinsic genomic instability of cyclin D1 (CCND1) overexpressing breast tumors. Therapeutic strategies may focus on disrupting the CCND1-CDK4/6 relationship through agents that downregulate cyclin D, inhibit CDK4/6 activity, or break cyclin D-CDK interactions. Biomarker-driven approaches targeting key elements of the CCND1-CDK4/6 oncogenic network can mitigate resistance. Further research is needed to understand the compensatory mechanisms related to intrinsic and acquired resistance. [21]\\u0026nbsp;\\u003c/p\\u003e\"},{\"header\":\"11. Conclusion and Implications for Clinical Practice\",\"content\":\"\\u003cp\\u003eBreast cancer is the most common malignant tumor. Research comparing the effectiveness of traditional chemotherapy and CDK-inhibitors in palliative care for metastatic breast cancer is crucial. This study analyzes data from an oncology information system, focusing on 975 breast cancer patients with sBRCA mutations. It evaluates patient survival post-metastatic diagnosis, differentiating between those treated with chemotherapy and those treated with CDK-inhibitors. Eleven variables were examined, including age, TNM staging, tumor biology, and treatment methods. Results show a clear survival disparity; 61% of patients starting CDK-inhibitors survived compared to 39% on chemotherapy. Moreover, risk ratios suggest CDK4/6 inhibitors are more effective than survival estimates from Cox regression analysis alone.\\u003c/p\\u003e\\n\\u003cp\\u003eBreast cancer represents the most prevalent malignant tumor worldwide, with increasing incidence rates across both genders. It remains a leading contributor to cancer-related mortality, particularly among women, with approximately 685,000 deaths attributed to the disease in 2020. Despite improvements in detection methodologies and awareness initiatives, a profound understanding of breast cancer\\u0026apos;s complexities is imperative. Numerous clinical investigations have explored its biological underpinnings and various therapeutic avenues. Recent findings highlight the potential of artificial intelligence in refining healthcare decisions and enhancing treatment outcomes, which may lead to improved survival statistics. Metastatic breast cancer, noted for the dissemination of malignant cells beyond the primary site, poses considerable therapeutic challenges. While a definitive cure remains elusive, available treatments can prolong life expectancy, although they often entail associated adverse effects. Notably, cyclin-dependent kinase (CDK) inhibitors have shown encouraging results, indicating enhanced progression-free survival compared to standard chemotherapy. Nevertheless, within the soBRCA cohort and patients undergoing chemotherapy-like regimens, overall survival rates did not exhibit significant disparities, as both treatment modalities resulted in similarly low survival outcomes.\\u003c/p\\u003e\"},{\"header\":\"References\",\"content\":\"\\u003col\\u003e\\n\\u003cli\\u003eF. Miglietta, M. Bottosso, G. Griguolo, M. V. Dieci, \\u0026quot;Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival,\\u0026quot; ESMO Open, vol. 7, no. 1, 2022. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eV. Lambert, S. Kane, B. Howidi, B. N. Nguyen, \\u0026quot;Systematic literature review of real-world evidence for treatments in HR+/HER2-second-line LABC/mBC after first-line treatment with CDK4/6i,\\u0026quot; BMC Cancer, vol. 24, 2024. springer.com\\u003c/li\\u003e\\n\\u003cli\\u003eR. Mir and K. Sharma, \\u0026quot;Isolated Bone Marrow Metastasis in Metastatic Carcinoma Breast: A Rare and Unique Case,\\u0026quot; Journal of Clinical Case Studies Reviews, 2024. researchgate.net\\u003c/li\\u003e\\n\\u003cli\\u003eF. Berger, M. Marce, S. Delaloge, A. C. Hardy-Bessard, et al., \\u0026quot;Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation,\\u0026quot; *BMJ Open*, 2022. bmj.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. Arnold, E. Morgan, H. Rumgay, A. Mafra, D. Singh, and others, \\u0026quot;Current and future burden of breast cancer: Global statistics for 2020 and 2040,\\u0026quot; The Breast, vol. 62, pp. 1-10, 2022. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. R. Lloyd, L. M. Spring, A. Bardia, et al., \\u0026quot;Mechanisms of resistance to CDK4/6 blockade in advanced hormone receptor\\u0026ndash;positive, HER2-negative breast cancer and emerging therapeutic opportunities,\\u0026quot; *Clinical Cancer Research*, vol. XX, no. YY, pp. ZZ-ZZ, 2022. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eA. Glaviano, S. A. Wander, R. D. Baird, K. C. H. Yap, et al., \\u0026quot;Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment,\\u0026quot; Drug Resistance, vol. 2024, Elsevier. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eJ. Huang, L. Zheng, Z. Sun, and J. Li, \\u0026quot;CDK4/6 inhibitor resistance mechanisms and treatment strategies,\\u0026quot; *Journal of Molecular*, vol. 2022, pp. 1-10, 2022. spandidos-publications.com\\u003c/li\\u003e\\n\\u003cli\\u003eA. B. S. Khorasani, N. Hafezi, M. J. Sanaei, \\u0026quot;The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances,\\u0026quot; Cell Biochemistry, vol. 2024, Wiley Online Library. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eM. Araghi, R. Mannani, A. Heidarnejad Maleki, et al., \\u0026quot;Recent advances in non-small cell lung cancer targeted therapy; an update review,\\u0026quot; *Cancer Cell*, vol. XX, no. YY, pp. ZZ-ZZ, 2023. Springer. springer.com\\u003c/li\\u003e\\n\\u003cli\\u003eJ. S. Lee, H. Hackbart, X. Cui, and Y. Yuan, \\u0026quot;CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions,\\u0026quot; *International Journal of Molecular*, vol. 2023. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eE. Agostinetto, G. Curigliano, and M. Piccart, \\u0026quot;Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar,\\u0026quot; Cell Reports Medicine, 2024. cell.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. D\\u0026apos;costa, A. Bothe, S. Das, and S. U. Kumar, \\u0026quot;CDK regulators\\u0026mdash;Cell cycle progression or apoptosis\\u0026mdash;Scenarios in normal cells and cancerous cells,\\u0026quot; Advances in Protein, vol. 2023, Elsevier, 2023. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eC. Greco, \\u0026quot;The nebula of chronicity: dealing with metastatic breast cancer in the UK,\\u0026quot; Anthropology \\u0026amp; medicine, 2022. tandfonline.com\\u003c/li\\u003e\\n\\u003cli\\u003eA. Asghar, T. A. Chohan, U. Khurshid, H. Saleem, \\u0026quot;A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression: Unlocking cellular and \\u0026hellip;,\\u0026quot; Chemico-Biological Interactions, vol. 2024, Elsevier. researchgate.net\\u003c/li\\u003e\\n\\u003cli\\u003eB. Smolarz, A. Z. Nowak, and H. Romanowicz, \\u0026quot;Breast cancer\\u0026mdash;epidemiology, classification, pathogenesis and treatment (review of literature),\\u0026quot; Cancers, 2022. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eT. Chen, E. Kharazmi, and M. Fallah, \\u0026quot;Race and ethnicity\\u0026ndash;adjusted age recommendation for initiating breast cancer screening,\\u0026quot; JAMA Network Open, 2023. jamanetwork.com\\u003c/li\\u003e\\n\\u003cli\\u003eR. E. Hendrick, M. A. Helvie, and D. L. Monticciolo, \\u0026quot;Breast cancer mortality rates have stopped declining in US women younger than 40 years,\\u0026quot; Radiology, 2021. rsna.org\\u003c/li\\u003e\\n\\u003cli\\u003eE. I. Obeagu and G. U. Obeagu, \\u0026quot;Breast cancer: A review of risk factors and diagnosis,\\u0026quot; Medicine, 2024. lww.com\\u003c/li\\u003e\\n\\u003cli\\u003eI. Schlam, J. Dower, and F. Lynce, \\u0026quot;Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?,\\u0026quot; Current Oncology Reports, 2024. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eM. Park, D. Kim, S. Ko, A. Kim, K. Mo, and H. Yoon, \\u0026quot;Breast cancer metastasis: mechanisms and therapeutic implications,\\u0026quot; *International Journal of \\u0026hellip;*, 2022. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eR. Hong and B. Xu, \\u0026quot;Breast cancer: an up‐to‐date review and future perspectives,\\u0026quot; Cancer communications, 2022. wiley.com\\u003c/li\\u003e\\n\\u003cli\\u003eD. T. Michaeli and T. Michaeli, \\u0026quot;Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new \\u0026hellip;,\\u0026quot; Journal of Clinical Oncology, 2022. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eL. Morrison, S. Loibl, and N. C. Turner, \\u0026quot;The CDK4/6 inhibitor revolution\\u0026mdash;a game-changing era for breast cancer treatment,\\u0026quot; Nature reviews Clinical oncology, 2024. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eE. Ferraro, E. M. Walsh, J. J. Tao, S. Chandarlapaty, \\u0026quot;Accelerating drug development in breast cancer: New frontiers for ER inhibition,\\u0026quot; *Cancer Treatment*, vol. 2022, Elsevier. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eP. M. Manohar and N. E. Davidson, \\u0026quot;Updates in endocrine therapy for metastatic breast cancer,\\u0026quot; Cancer Biology \\u0026amp; Medicine, 2022. cancerbiomed.org\\u003c/li\\u003e\\n\\u003cli\\u003eL. Cucciniello, L. Gerratana, L. Del Mastro, et al., \\u0026quot;Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?,\\u0026quot; *Cancer Treatment*, vol. XX, no. YY, pp. ZZ-ZZ, 2022. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eV. Srivastava, U. Devi, K. R. Nackwal, M. Z. Ahmed, \\u0026quot;In silico identification of novel CDK4 inhibitors for retinoblastoma,\\u0026quot; Chemical Physics, vol. 2024, Elsevier. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. Shrestha, D. Y. Wang, Y. Ben-David, and E. Zacksenhaus, \\u0026quot;CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer,\\u0026quot; Oncogenesis, 2023. nature.com\\u003c/li\\u003e\\n\\u003cli\\u003eN. Koirala, N. Dey, J. Aske, and P. De, \\u0026quot;Targeting cell cycle progression in HER2+ breast cancer: an emerging treatment opportunity,\\u0026quot; *International Journal of Molecular \\u0026hellip;*, vol. 2022. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eS. Duro-S\\u0026aacute;nchez, M. Nadal-Serrano, et al., \\u0026quot;Therapy-induced senescence enhances the efficacy of HER2-targeted antibody\\u0026ndash;drug conjugates in breast cancer,\\u0026quot; *Cancer*, vol. 2022. aacrjournals.org\\u003c/li\\u003e\\n\\u003cli\\u003eM. Abdelmalak, R. Singh, M. Anwer, P. Ivanchenko, \\u0026quot;The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance,\\u0026quot; Cancers, 2022. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. Zhang, L. Zhang, R. Hei, X. Li, and H. Cai, \\u0026quot;CDK inhibitors in cancer therapy, an overview of recent development,\\u0026quot; *American Journal of \\u0026hellip;*, vol. 2021. nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eG. S. Chaudhry, A. Md Akim, Y. Y. Sung, et al., \\u0026quot;Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics,\\u0026quot; *Frontiers in \\u0026hellip;*, 2022. frontiersin.org\\u003c/li\\u003e\\n\\u003cli\\u003eC. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılı\\u0026ccedil;, et al., \\u0026quot;Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy,\\u0026quot; BMC Cancer, vol. 23, no. 1, 2023. springer.com\\u003c/li\\u003e\\n\\u003cli\\u003eH. Li, Y. Wu, H. Zou, S. Koner, J. K. Plichta, and S. M. Tolaney, \\u0026ldquo;/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA \\u0026hellip;,\\u0026rdquo; The Lancet, 2024. thelancet.com\\u003c/li\\u003e\\n\\u003cli\\u003eS. Cavalu, A. M. Abdelhamid, S. Saber, et al., \\u0026quot;Cell cycle machinery in oncology: A comprehensive review of therapeutic targets,\\u0026quot; The FASEB Journal, vol. 2024, Wiley Online Library. wiley.com\\u003c/li\\u003e\\n\\u003cli\\u003eH. K. Ahn, J. Y. Kim, K. H. Lee, G. M. Kim, S. Y. Kang, et al., \\u0026quot;\\u0026hellip; with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study,\\u0026quot; The Lancet, 2025. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eE. Panagiotou, G. Gomatou, I. P. Trontzas, \\u0026quot;Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials,\\u0026quot; *Clinical and Translational Oncology*, vol. 2022, Springer. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eB. Lin, K. Wang, Y. Yuan, Y. Wang, Q. Liu, and Y. Wang, \\u0026quot;A novel approach to the analysis of Overall Survival (OS) as response with Progression-Free Interval (PFI) as condition based on the RNA-seq expression data in The \\u0026hellip;,\\u0026quot; BMC ..., vol. 2024, Springer. springer.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. Valente, I. Chirico, G. Ottoboni, and R. Chattat, \\u0026quot;Relationship dynamics among couples dealing with breast cancer: a systematic review,\\u0026quot; *International Journal of \\u0026hellip;*, 2021. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eI. Ge, K. Berner, M. Mathis, C. Hensgen et al., \\u0026quot;Real-World Data Analysis of CDK4/6 Inhibitor Therapy\\u0026mdash;A Patient-Centric Single Center Study,\\u0026quot; 2024. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eJ. Wang and S. G. Wu, \\u0026quot;Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives,\\u0026quot; Breast Cancer: Targets and Therapy, 2023. tandfonline.com\\u003c/li\\u003e\\n\\u003cli\\u003eT. Engler, P. A. Fasching, D. L\\u0026uuml;ftner, \\u0026quot;Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients\\u0026ndash;Data from the Real-World Registry,\\u0026quot; Geburtshilfe und Frauenheilkunde, vol. 82, no. 9, pp. 1070-1079, 2022. thieme-connect.com\\u003c/li\\u003e\\n\\u003cli\\u003eP. M. Parikh, A. Vora, R. Yadav, A. Kapoor, et al., \\u0026quot;Consensus guidelines for the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in the management of hormone receptor positive (HR+ ve), Her2\\u0026minus; ve early breast cancer,\\u0026quot; South Asian Journal, 2024. thieme-connect.com\\u003c/li\\u003e\\n\\u003cli\\u003eC. Kappel, M. J. Elliott, V. Kumar, M. B. Nadler et al., \\u0026quot;Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer,\\u0026quot; 2024. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eN. Ashai and S. M. Swain, \\u0026quot;Post-CDK 4/6 inhibitor therapy: current agents and novel targets,\\u0026quot; Cancers, 2023. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eLQ Cao, H. Sun, Y. Xie, H. Patel, L. Bo, H. Lin, \\u0026quot;Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy,\\u0026quot; Frontiers in ..., 2024. frontiersin.org\\u003c/li\\u003e\\n\\u003cli\\u003eJ. Wang, Y. Han, J. Wang, Q. Li et al., \\u0026quot;Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis,\\u0026quot; 2022. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eC. H. Ke, C. N. Lin, and C. S. Lin, \\u0026quot;Hormone, Targeted, and combinational therapies for breast cancers: from humans to dogs,\\u0026quot; International journal of molecular sciences, 2024. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eA. Walia, J. Tuia, and V. Prasad, \\u0026quot;Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed,\\u0026quot; Nature Reviews Clinical Oncology, 2023. escholarship.org\\u003c/li\\u003e\\n\\u003cli\\u003eJ. Ma, J. J. Chan, C. H. Toh, and Y. S. Yap, \\u0026quot;Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer,\\u0026quot; NPJ Breast Cancer, 2023. nature.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. Cejuela, A. Gil-Torralvo, M.\\u0026Aacute;. Castilla, \\u0026quot;Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer,\\u0026quot; *International Journal of \\u0026hellip;*, 2023. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eY. Yang, J. Wang, W. Wang, T. Zhang, J. Zhao, \\u0026quot;Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung,\\u0026quot; *Frontiers in Oncology*, vol. 2022. frontiersin.org\\u003c/li\\u003e\\n\\u003cli\\u003eB. X. He, Y. F. Zhong, Y. B. Zhu, J. J. Deng, \\u0026quot;\\u0026hellip; for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall \\u0026hellip;,\\u0026quot; *Translational Lung*, 2022. nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eC. Molinelli, M. Bruzzone, E. Blondeaux, T. Ruelle, \\u0026quot;... of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world \\u0026hellip;,\\u0026quot; Journal of Cancer, vol. 2024, Elsevier. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. P. Goetz, M. Toi, J. Huober, J. Sohn, O. Tr\\u0026eacute;dan, I. H. Park, and others, \\u0026quot;Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\\u0026minus; advanced breast cancer: final overall survival results of MONARCH 3,\\u0026quot; Annals of ..., vol. 2024, Elsevier. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eI. M. Stanciu, A. I. Parosanu, and C. Nitipir, \\u0026quot;An overview of the safety profile and clinical impact of CDK4/6 inhibitors in breast cancer\\u0026mdash;a systematic review of randomized phase II and III clinical trials,\\u0026quot; Biomolecules, 2023. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eN. P. McAndrew and R. S. Finn, \\u0026quot;Clinical review on the management of hormone receptor\\u0026ndash;positive metastatic breast cancer,\\u0026quot; JCO oncology practice, 2022. ascopubs.org\\u003c/li\\u003e\\n\\u003cli\\u003eI. M. Stanciu, A. Ioana Parosanu, and C. Nitipir, \\u0026quot;An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer\\u0026mdash;A Systematic Review of Randomized Phase II and III Clinical Trials,\\u0026quot; 2023. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eJ. T. Thiel, A. Daigeler, J. Kolbenschlag, K. Rachunek, \\u0026quot;The role of CDK pathway dysregulation and its therapeutic potential in soft tissue sarcoma,\\u0026quot; Cancers, vol. 2022. mdpi.com\\u003c/li\\u003e\\n\\u003cli\\u003eZ. Li, W. Zou, J. Zhang, Y. Zhang et al., \\u0026quot;Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer,\\u0026quot; 2020. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eL. Cornell, S. A. Wander, T. Visal, N. Wagle et al., \\u0026quot;MicroRNA-Mediated Suppression of the TGF-\\u0026beta; Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance,\\u0026quot; 2019. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eI. Segatto and M. C. Mattevi, \\u0026quot;\\u0026hellip; luminal breast cancer patient‐derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors,\\u0026quot; The Journal of \\u0026hellip;, 2024. wiley.com\\u003c/li\\u003e\\n\\u003cli\\u003eW. C. Yang, M. F. Wei, Y. H. Lee, C. S. Huang et al., \\u0026quot;Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair \\u0026hellip;,\\u0026quot; Translational Oncology, 2024. sciencedirect.com\\u003c/li\\u003e\\n\\u003cli\\u003eB. C. Chandler, M. Liu, L. M. Lerner, C. A. Nino, and others, \\u0026quot;RB expression confers sensitivity to CDK4/6 inhibitor\\u0026ndash;mediated radiosensitization across breast cancer subtypes,\\u0026quot; JCI, 2022. nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eA. S. Clark, F. Hong, R. S. Finn, A. M. DeMichele, et al., \\u0026quot;Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B,\\u0026quot; *Clinical Cancer Research*, vol. 2023. aacrjournals.org\\u003c/li\\u003e\\n\\u003cli\\u003eA. K. Witkiewicz, E. Schultz, J. Wang, D. Hamilton, et al., \\u0026quot;Determinants of response to CDK4/6 inhibitors in the real-world setting,\\u0026quot; NPJ Precision Oncology, 2023. nature.com\\u003c/li\\u003e\\n\\u003cli\\u003eKCC Johnson, D. Quiroga, P. Sudheendra, and others, \\u0026quot;Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer\\u0026ndash;a review of current evidence for and against the use of anti-HER2 treatment regimens,\\u0026quot; *Expert Review of Anticancer Therapy*, vol. 22, no. 5, pp. 1-12, 2022. nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eF. Scirocchi, S. Scagnoli, A. Botticelli, A. Di Filippo, et al., \\u0026quot;Immune effects of CDK4/6 inhibitors in patients with HR+/HER2\\u0026minus; metastatic breast cancer: relief from immunosuppression is associated with clinical response,\\u0026quot; The Lancet, 2022. thelancet.com\\u003c/li\\u003e\\n\\u003cli\\u003eT. O. Staff, \\u0026quot;Kaklamani Discusses Approach to CDK4/6 Inhibitor and Later Therapy for ER+ Breast Cancer,\\u0026quot; 2024. targetedonc.com\\u003c/li\\u003e\\n\\u003cli\\u003eM. Will, J. Liang, C. Metcalfe, and S. Chandarlapaty, \\u0026quot;Therapeutic resistance to anti-oestrogen therapy in breast cancer,\\u0026quot; Nature Reviews Cancer, 2023. nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eF. Miranda, H. Prazeres, F. Mendes, D. Martins, \\u0026quot;Resistance to endocrine therapy in HR+ and/or HER2+ breast cancer: the most promising predictive biomarkers,\\u0026quot; *Molecular Biology*, vol. 2022, Springer. researchgate.net\\u003c/li\\u003e\\n\\u003cli\\u003eF. Andre, N. Ismaila, K. H. Allison, W. E. Barlow, et al., \\u0026quot;Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update,\\u0026quot; *Journal of Clinical Oncology*, vol. 2022. ascopubs.org\\u003c/li\\u003e\\n\\u003cli\\u003eW. Buller, L. Pallan, T. Chu, \\u0026quot;CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset,\\u0026quot; Journal of Oncology, 2023. [HTML]\\u003c/li\\u003e\\n\\u003cli\\u003eD. Jin, N. Tran, N. Thomas, and D. D. Tran, \\u0026quot;Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity,\\u0026quot; 2019. ncbi.nlm.nih.gov\\u003c/li\\u003e\\n\\u003cli\\u003eL. Zhu, Q. Yang, R. Hu, Y. Li, Y. Peng, H. Liu, and M. Ye, \\u0026quot;Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib,\\u0026quot; *Scientific Reports*, 2022. nature.com\\u003c/li\\u003e\\n\\u003c/ol\\u003e\"}],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":true,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":true,\"hideJournal\":true,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":false,\"isAuthorSuppliedPdf\":false,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":false,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true},\"keywords\":\"\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-8494703/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-8494703/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"Metastatic breast cancer (MBC), particularly the hormone receptor–positive/HER2-negative subtype, remains an incurable disease with limited long-term therapeutic success. The advent of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has transformed the treatment landscape, yet their comparative benefit over conventional chemotherapy in real-world clinical settings remains incompletely defined. In this study, we performed a comprehensive comparative analysis of CDK4/6 inhibitors and standard chemotherapy regimens in patients with metastatic breast cancer, integrating evidence from randomized clinical trials, network meta-analyses, and real-world observational data. Outcomes assessed included progression-free survival, overall survival, treatment tolerability, and quality-of-life measures. Our findings demonstrate that CDK4/6 inhibitors, particularly when combined with endocrine therapy, consistently provide superior progression-free survival and improved tolerability compared with conventional chemotherapy, with trends toward improved overall survival in selected patient populations. Resistance mechanisms, molecular predictors of response, and the role of combination strategies targeting parallel signaling pathways are also discussed. These results support the preferential use of CDK4/6-based regimens as a cornerstone of therapy for hormone receptor–positive metastatic breast cancer and highlight the need for biomarker-driven treatment optimization to overcome therapeutic resistance.\",\"manuscriptTitle\":\"Comparative Analysis of the Effectiveness of CDK Inhibitors and Conventional Chemotherapy in Metastatic Breast Cancer\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2026-01-05 06:59:40\",\"doi\":\"10.21203/rs.3.rs-8494703/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true}}],\"origin\":\"\",\"ownerIdentity\":\"7a1944f8-d12d-47fc-b8da-fb36f9b2b0ec\",\"owner\":[],\"postedDate\":\"January 5th, 2026\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"posted\",\"subjectAreas\":[{\"id\":60544417,\"name\":\"Biological sciences/Biochemistry\"},{\"id\":60544418,\"name\":\"Health sciences/Medical research/Genetics research\"}],\"tags\":[],\"updatedAt\":\"2026-01-06T16:25:44+00:00\",\"versionOfRecord\":[],\"versionCreatedAt\":\"2026-01-05 06:59:40\",\"video\":\"\",\"vorDoi\":\"\",\"vorDoiUrl\":\"\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-8494703\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-8494703\",\"identity\":\"rs-8494703\",\"version\":[\"v1\"]},\"buildId\":\"XKTyCvWXoU3ODBz1xrDgd\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}